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Abstract
Purpose
Individual optimized treatment planning is recommended when creating treat-
ment plans for brachytherapy of cervical cancer. Manual alteration of the dose
distribution is time consuming and the treatment plan may be dependent on the
person creating it. Inverse planning simulated annealing (ipsa) is an algorithm
that can optimize the dose distribution considering dose to several delineated
stuctures. This algorithm, currently available in the treatment planning system
Masterplan, has been evaluated for brachytherapy of cervical cancer.
The Masterplan system simulates a source type from at diﬀerent manufacturer
than the type used for treatment at St. Olavs Hospital at the time being. The
dose distribution from the two source types were evaluated to see if Masterplan
can be used to simulate the source type used for treatment at St. Olavs Hospital.
Methods and materials
The dose distributions from the two source types were compared based on calcu-
lations from two treatment planning systems (Masterplan and Plato) simulating
each source type.
Dose measurements of the source used at St. Olavs Hospital for brachytherapy
treatment of cervical cancer were taken. These were compared with the dose
distribution calculated by the two treatment planning systems.
At St. Olavs Hospital treatment are executed using a Fletcher type applicator.
mr-images are taken with the applicator in place. Target and organs at risk
are delineated in the images before the treatment planning is performed. For 11
patients treated with brachytherapy of cervical cancer at St. Olavs Hospital, three
diﬀerent ipsa-plans with diﬀerent dose constraints (ispa1, ipsa2 and ipsa3) and
one treatment plan with equal dwell times were made in retrospect. All ipsa-plans
constrain the same dose to the target. ipsa1 and ipsa3 have the same constraints
to organs at risk, while ipsa2 allow a higher dose to the organs at risk. ipsa3 sets
a limit for maximum dose in target volume. For evaluation of the quality of the
treatment plans, dose parameters of clinical relevance were extracted from dose
volume histograms.
Results
Deviations in the calculated dose distribution up to 30% is found for the two
source types in certain areas. These deviations are found close to the source
and below the connector end of the source. For distances ≥ 4 mm from the
source center along one axis, deviations of the calculations were ≤ 4%. This is in
correspondance with the measured dose values.
Target coverage for ipsa2 is 0.92. For ispa1 and ipsa3 target coverage is 0.84
and 0.81 respectively. The number of treatment plans exceeding tolerance limit
for one or more oar is 82% for ipsa2, 55% for ipsa1 and 35% for ipsa3. The plan
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with equal dwell times have a target coverage of 0.66 and 45% of the treatment
plans exceed the given tolerance limit for one or more organs at risk.
Conclusion
Deviations are found in the simulated dose distribution of the two source types
tested, but only in clinical irrelevant areas for brachytherapy of cervical cancer.
Masterplan can be used for simulating the dose distribution of the source used
for treatment at St. Olavs Hospital.
Using ipsa is better when it comes to improving target coverage and not
violating tolerance limit for organs at risk, than a conservative treatment plan
with equal dwell times. Due to too high doses to organs at risk, ipsa2 should
be rejected. ipsa1 has better target coverage and ipsa3 have lower dose to the
organs at risk. To avoid inhomogeneities in dwell time values, ispa3 is probably
the best suggestion.
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Sammendrag
Formål
Det er anbefalt å lage individuelt optimaliserte planer når behandlingsplaner skal
lages i forbindelse med brachyterapi av livmorhalskreft. Manuell endring av dose-
fordelingen er tidkrevende og resultatet kan bli preget av personen som lager
planen. 'Iverse planning simulated annealing' (ipsa) er en algoritme som kan
optimalisere dosefordelingen slik at dose til ﬂere skisserte strukturer blir tatt hen-
syn til. Denne algoritmen, tilgjengelig i doseplanleggingssystemet Masterplan,
har blitt vurdert for brachyterapi av livmorhalskreft.
Masterplan simulerer en kildetype fra en annen produsent enn den kildetypen
som blir brukt til behandling på St. Olavs hospital i dag. Dosefordelingen til de
to kildetypene har blitt vurdert for å se om Masterplan kan brukes til å simulere
kildetypen brukt til behandling.
Metode og utstyr
Dosefordelingen fra de to kildetypene ble sammenlignet ved hjelp av dosebereg-
ninger fra to doseplanleggingssystemer (Masterplan og Plato) som simulerer hver
sin kildetype.
Det ble tatt målinger av dosen fra kilden brukt på St. Olavs hospital til
brachyterapi av livmorhalskreft. Disse ble sammenlignet med dosefordelingen
regnet ut av de to planleggingssystemene.
På St. Olavs hospital blir en Fletcher type applikator brukt til behandling.
mr-bilder blir tatt etter at applikatoren er posisjonert. I bildene blir målvolum
og risikooganer skissert før behandlingsplanleggingen gjennomføres. I denne stu-
dien har tre ulike ipsa-planer med forskjellig doserestriksjoner (ispa1, ipsa2 and
ipsa3) og en plan med lik liggetid i kildeposisjonene, blitt laget i ettertid for 11
pasienter behandlet for livmorhalskreft på St. Olavs hospital. ispa-planene har
samme doserestriksjoner til målvolum. ipsa1 og ipsa3 har samme begrensning
til risikoorganer, mens ipsa2 tillater høyere dose til risikoorganer. ipsa3 har
en begrensning for maksimum dose til volum for målvolumet. For vurdering av
kvaliteten til planene ble klinisk relevante doseparametre funnet fra dosevolum-
histogram.
Resultat
Det ble funnet avvik opp til 30% for beregnet dose i ulike punkt for de to
kildetypene i visse områder. Disse avvikene ligger nærme kilden og rett under
koblingsenden. For avstander ≥ 4 mm fra kildesenter transversalt på kilden er
avvikene i beregningene ≤ 4%. Dosemålingene som ble tatt støtter dette.
Dekning av målvolum er 0.92 for ipsa2. For ipsa1 og ipsa3 er denne deknin-
gen henholdsvis 0.84 og 0.81. Antall planer hvor en deﬁnert grense for dosen til
et eller ﬂere risikoorgan har blitt oversteget, er 82% for ipsa2, 55% for ipsa1 og
35% for ipsa3. Planen hvor liggetidene er fordelt likt har målvolumdekning på
v
0.66 og 45% av planene overstiger den deﬁnerte toleranse grensen for et eller ﬂere
risikoorgan.
Konklusjon
Det ble funnet avvik i de simulerte dosefordelingene mellom de to kildetypene, men
kun i klinisk irrelevante områder for brachyterapi av livmorhalskreft. Masterplan
kan bli brukt til å simulere dosefordelingen til kilden som blir brukt til behandling
på St. Olavs hospital.
Bruk av ipsa gir bedre resultater enn den konservative behandlingsplanen med
lik liggetid når det gjelder dekning av målvolum og å overholde toleransegrensene
som er satt for risikorganene. På grunn av for høye doser til risikoorganer burde
ipsa2 forkastes. ipsa1 gir bedre dekning av målvolum mens ipsa3 gir lavere
dose til risikoorganer. For å unngå store forskjeller mellom liggetidene i de ulike
kildeposisjonene vil antagelig ipsa3 gi best utganspunkt for videre planlegging.
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Abbreviations
KERMA dEtrdm - The sum of the initial kinetic energy of all charged ionizing
particles released in a material, dm. (Gy)
Air KERMA rate Kerma to air, in air, at 1 m reference distance, corrected for
scatter and attenuation (µGy/h)
CTV Clinical target volume
OAR Organ at risk
Normal tissue All body tissue not deﬁned as target or oar
CTV D90 The minimum dose in 90% of the target volume (Gy)
CTV V100 The target volume receiving the prescribed dose (cm3)
CTV V400 The target volume receiving 400% of the prescribed dose (cm3)
EXT V100 The volume of normal tissue receiving the prescribed dose (cm3)
OARD2 cm3 The minimum dose in the 2 cm3 volume receiving the highest dose
of the given oar (Gy)
IPSA Inverse planning simulated annealing
EDT Plan with equal dwell times
DVH Dose volume histogram
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1 Introduction
The ninth most common type of cancer in Norway is cervical cancer. The inci-
dence of cervical cancer has been decreasing over the last 40 years, mostly due
to systematic screening of all women between 25 and 69. Every year 270 new
incidences of cervical cancer occur (2004). The lethality is 0.37. Half of the
women where cervical cancer is demonstrated have never taken the cell test in the
screening routine, and the cancer stage is often advanced [2].
While early stage cervical cancer is usually treated surgically, locally advanced
cervical cancer is treated with intracavitary brachytherapy in combination with
external radiotherapy and chemotherapy. The aim of radiotherapy is to give high
doses to tumor tissue, while sparing the adjacent normal tissue. Functionality of
nearby organs may be reduced or damaged if the organs receive too high doses.
Traditionally there were little information available of a patient's individual
anatomy when creating a treatment plan for intracavitary brachytherapy. There-
fore standard treatment plans were used. The radiation dose was prescribed to
a geometrical point A considered to be representative for the minimum dose to
most malignant tissue [3]. 3D imaging techniques have now become available,
and with the information from these images it is possible to create individually
optimized treatment plans.
From international recommendations, treatment planning of cervical cancer
should be based on individual anatomy [4]. Several hospitals, including St. Olavs
Hospital, have started using individually optimized treatment plans. Treatment
plans are manually altered to get the desired dose distribution, i.e. an optimized
treatment plan. This is time consuming. To save time and to make the treatment
planning less subjective, an inverse planning simulated annealing (ipsa) algo-
rithm has been suggested. This algorithm is currently available in the treatment
planning system Masterplan.
ipsa imports dose constraints set by the radiotherapist, and ﬁnds the best
possible solution matching these constraints. Diﬀerent constraints can be speciﬁed
[5]. In the present study, three diﬀerent sets of dose constraints have been tested.
The ipsa-optimized treatment plans are also compared to a more conservative
treatment plan.
This is a retrospective study where four diﬀerent treatment plans have been
made for patients that previously have been treated at St. Olavs Hospital.
The ipsa module currently available in Masterplan, simulates a source type
from a diﬀerent manufacturer than the one used at St. Olavs Hospital. The
geometries of these two source types are slightly diﬀerent [6], and therefore it is
important to examine if and how the dose distribution around the two source
types diﬀer and how this clinically aﬀect the brachytherapy treatment of cervical
cancer.
3
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2 Theory
2.1 Brachytherapy of cervical cancer
2.1.1 Brachytherapy
Brachytherapy is a form of radiation therapy where a radioactive source is placed
within or in close proximity to the volume requiring treatment. For intracavi-
tary brachytherapy (icbt) the source is placed in body cavities, and a common
application of icbt is treatment of cervical cancer.
In brachytherapy the dose fall-oﬀ around the radioactive source is rapid. This
makes it possible to deliver a high dose to the tumor volume, while at the same
time reduce the dose to the surrounding tissue. Diﬀerent dose rates can be used;
low dose rate (ldr), medium dose rate (mdr) and high dose rate (hdr). If the
dose rate delivered is high (hdr: ≥ 12 Gy/h), the treatment time is short (ca
5− 15 min) and the number of fractions are limited. Short overall treatment time
reduces the risk of tumor repopulation [3].
Diﬀerent radioactive sources can be used for icbt. At St. Olavs Hospital the
equipment is adapted to 192Iridium, a commonly used source for icbt. This is
a γ-emitter, as most sources used in brachytherapy (β-emitting sources are more
common for shallow lesions). One of the reasons for using 192Iridium is the high
speciﬁc activity (activity per unit mass of a radionuclide). This gives a high dose
rate, and also helps miniaturization of brachytherapy sources [3].
2.1.2 Cervical cancer
The uterus is situated in the central part of the pelvis, between the bladder and
the rectum. The lower part of the uterus is called cervix uteri. Most incidences
of cervical cancer have its origin from the mucous membrane between the outer
part of the cervix and the vagina, see ﬁgure 1 [2].
Figure 1: Illustration of the region where most incidences of cervical cancer have
its origin. The vagina is shown in the bottom part of the picture, the upper part
shows the uterus. One ovary is drawn to the right [2].
Early stage cervical cancer is usually treated surgically. Exceptions are made
by risk of complications because of comorbidity. Locally advanced cervical cancer
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is treated with chemoradiation. At St. Olavs Hospital the standard treatment is
external radiation treatment combined with weekly Cisplatin and brachytherapy,
where icbt plays a very important role in the attempt to cure the patient. This
treatment is chosen whenever surgery alone is unlikely to cure the patient [7][8].
2.1.3 Target volumes in brachytherapy of cervical cancer
The Groupe Europeen de Curietherapie - European Society for Therapeutic Ra-
diology and Oncology (gec-estro) working group has made recommendations
on how to delineate target volumes on digital images in brachytherapy of cervical
cancer [4]. The gross tumor volume, gtv, should include the gross demonstrable
extent and location of the malignant growth. The clinical target volume, ctv, is
deﬁned as the volume containing both gtv and subclinical microscopic malignant
disease [9]. The ctv is divided into two subvolumes for radiotherapy planning
purposes. High risk ctv (hr ctv) includes gtv, the whole cervix and the pre-
sumed extracervical tumor extension. No safety margins are added. Intermediate
risk ctv (ir ctv) encompasses high risk ctv with safety margin of 5− 15 mm.
Safety margin is chosen according to tumor size and location, potential tumor
spread, tumor regression and treatment strategy. Examples of the delineated vol-
umes are shown in ﬁgure 2. All tissue included in ctv should be neutralized in
order to cure the patient [3].
(a) Frontal plane (b) Transversal plane
Figure 2: Illustration of gtv and ctv in brachytherapy treatment of cervical
cancer [4].
2.1.4 Applicators
To perform brachytherapy treatment of cervical cancer an applicator is inserted
into the uterus and inner part of vagina. The applicator is connected to a re-
mote afterloader, which loads the source into the applicator for treatment. The
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afterloader system applied in this study uses a stepping source, i.e. one source is
placed in diﬀerent positions in the applicator for a certain amount of time to give
the desired dose distribution [3].
Two diﬀerent types of applicators are widely used for brachytherapy of cervical
cancer, namely Fletcher type and ring type. Both consist of a central uterine
applicator that is positioned in the uterus. In addition to this, the Fletcher
applicator have two ovoid applicators and the ring type has a ring applicator,
both placed in the inner part of the vagina close to the cervix. Both of the
applicator types have the possibility to geometrically ﬁt to diﬀerent anatomical
structures and pathological situations for the individual patient. The two diﬀerent
applicator types are shown in ﬁgure 3.
(a) Ring type (b) Fletcher type
Figure 3: Ring and Fletcher type applicators.
At St. Olavs Hospital a Fletcher type applicator is used. This applicator
was developed by Fletcher, who made a system for radium that consists of a
rigid metallic intrauterine applicator and two ovoid applicators. Subsequently
this system was modiﬁed, ﬁrst for manual afterloading, and later also for remote
afterloading. It has also been adapted to the use of diﬀerent sources [3]. The
Fletcher type used at St. Olavs Hospital is shown in ﬁgure 4.
Figure 4: The Fletcher type applicator used at St. Olavs Hospital [10].
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2.1.5 Treatment techniques
Diﬀerent traditions for treatment techniques of brachytherapy of cervical cancer
exist. These diﬀerent systems are sets of rules based on applicator type, geometry
and source intensity, in order to give the best dose distribution in the target
volume.
The three main systems are the Stockholm-, Paris- and Manchester system
[3]. The Stockholm system is based on a ring applicator, the Paris system is based
on a 'mould' individual shaped applicator while the Manchester system is based
on an applicator consisting of an uterine- and to ovoid applicators.
Traditionally the Fletcher and ring applicators have been used with standard
treatment plans. The standard treatment plan formerly used at St. Olavs Hospital
was developed from the Manchester system, where the dose was prescribed to a
so-called point A. Point A was considered to be representative for the minimum
dose to most of the malignant tissue and is deﬁned from the geometry of the
applicator. A plan made on the basis of dose to point A does not take into
consideration the variation of the anatomy between diﬀerent patients.
With 3D-image techniques available today it is possible to make individual
treatment plans for every patient. Target volume and organs at risk (oars) can
be delineated from ct or mr-images, and then it is possible to create a treatment
plan with best possible ﬁtting of isodose lines to the target volume, and at the
same time give acceptable doses to the oars. gec-estro working group has
recommended that target volume should be the basis of dose distribution, and
not the dose to point A [4].
Fitting the isodose lines to the target volume and the organs at risk are usually
done manually in a treatment planning system. Recently new computer programs
have become available for inverse optimization planning, where the program can
consider both target volume and the dose to other delineated structures.
2.1.6 Organs at risk
The use of radiation therapy inevitably involves exposure to the surrounding
normal tissue. Some healthy tissue tolerates curative radiation doses rather well,
while for other organs the consequences of irradiation are severe. The dose must
then be tailored to minimize the likelihood of serious injury. The pathological
process of radiation injury begins immediately after radiation exposure, but the
clinical outcome may not become apparent for weeks, months or years later [11].
When symptoms appear during treatment or within a few weeks after, the eﬀect is
deﬁned as acute. This eﬀect is most prominent in tissue with rapidly proliferating
cells. Late eﬀects come from tissue with a slow turnover, and the symptoms might
not emerge before months or years after treatment. The eﬀects on the surrounding
tissue are dependent on total dose, dose per fraction and fractionation rate [12].
When radiation therapy is performed in a certain region, a number of local
organs can be speciﬁed as oars. These organs are either in close proximity to the
tumor or they are radiosensitive and this will inﬂuence the treatment planning.
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Damage to one of these organs may reduce the quality of life of the patient, and
keeping doses under the tolerance limits for these organs are of great importance
during treatment planning. For radiation of cervical cancer these speciﬁed oars
are bladder, rectum and sigmoid [3][13].
The tolerance dose of the oar depends upon the organs functional reserve and
structural organization. Organs are often divided into two groups physiologically;
parallel-like and serial-like. This is analogous to an electrical circuit, where a
shunt circuit will still function after damage in one part of the circuit, but a serial
connection will not. Parallel like organs are for example kidney and liver, and
damage to parts of these organs will only lower the functionality, not fully damage
the organ. A typical serial like organ is the spinal cord, were a patient can be
paralyzed after damage to only a small fraction of the organ. Bladder, rectum
and sigmoid are all serial like organs, where damage to parts of this organ can
damage the functionality by for instance making a hole in the organ wall [9].
Due to this fact, small organ volumes irradiated with the tolerance dose or
higher, is of greater interest than the average dose to the entire volume of the
organ when assessing late eﬀects of oars from brachytherapy of cervical cancer.
In addition to this, the dose delivered to the typical oars from brachytherapy is
inhomogeneous, unlike what is assumed for external beam radiation therapy. The
part of the organs that is situated adjacent to the radiation source will receive a
much higher dose than the parts further away. This is visualized in ﬁgure 5.
Figure 5: Schematic anatomical diagram indicating the most irradiated tissue
volumes in oars (0.1, 1 and 2 cm3) in brachytherapy of cervical cancer [13].
There is also a general agreement that correlating point doses and dose volume
eﬀects is insuﬃcient, since damage to a point is not of clinical relevance. The dose
will not be of clinical relevance until a certain size of the oar reaches a tolerance
level. For bladder, rectum and sigmoid this critical size is correlated with the
thickness of the organ wall, and if this volume is irradiated with more than the
tolerance dose, there is a large probability for damaging the function of the oar.
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Therefore it is recommended to indicate the lowest dose to the limited volume of
the oar that receives the highest dose. This bear clinical relevance. Regarding
bladder, rectum and sigmoid, a volume of 2 cm3 is recommended. Dose to this
volume should correlate to side eﬀects [13].
The oars are presumed to have a given tolerance dose for the total treatment,
external and internal radiotherapy. The minimum dose in the 2 cm3-volume re-
ceiving the highest dose of the oar, should not exceed this tolerance limit. From
recommendations from R. Pötter [14], the limit for the bladder is 90 Gy and for
rectum and sigmoid it is 75 Gy. These limits are calculated into biological doses
relative to 2 Gy fractions (equation (1)).
2.1.7 Biological equivalent dose
Biological equivalent dose after diﬀerent radiation regimen can be calculated by
means of the linear quadratic model. Here, biological dose of each fraction can be
recalculated to show similar eﬀect as if the dose is given in 2 Gy fractions. Since
brachytherapy often is given with fraction doses ≥ 2 Gy, these doses need to be
calculated into 2 Gy fractions. This is done by using equation (1), where eqd2 is
the biologically equivalent dose given with fraction dose of 2 Gy.
EQD2 = nd ·
d+ αβ
2 + αβ
(1)
In equation (1) n is the number of fractions, d is the dose per fraction and
α/β-ratio is the dose at which the linear (α) and quadratic (β) components of
cell killing are equal from the linear-quadratic model [12]. This formula is used
to calculate the total biologically weighted dose from all fractions, from both
external and internal radiation therapy. For cervical cancer, gec-estro working
group recommends to use α/β = 10 for tumor tissue (early responding tissue),
and α/β = 3 for the oars; bladder, rectum and sigmoid (late responding tissue)
[13]. A higher α/β-value for bladder has also been suggested (α/β = 5 − 10)
[15], which will result in a lower equivalent dose converted into 2 Gy fractions
if the fractionation is the same. Using α/β = 3 gives a higher equivalent dose,
and therefore, to be conservative, this value is chosen when converting to 2 Gy
fractions [13].
2.2 Radiation dosimetry
2.2.1 Source types of interest
An aim of this work was to implement the brachymodule in the treatment planning
system Masterplan in the routine at St. Olavs Hospital. The vendor of Masterplan
does not support the source used for treatment at St. Olavs Hospital. Therefore
an evaluation of the diﬀerent source types was needed in order to see if the source
type available in Masterplan can be used to simulate the treatment source. The
source used for treatment at St. Olavs Hospital is speciﬁc for the GammaMed
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12i hdr brachytherapy system. A source type available in Masterplan, Nucletron
hdr classic, has similar geometry to the GammaMed source.
Both these source types are made of 192Ir, which is one of the more stable
radioisotopes of Iridium. The half life is 73.8 days, which is considerably longer
than one fraction of brachytherapy, but replacement of the source is necessary
every third month. The speciﬁc activity is high (9.2 Ci/g), making it suitable for
brachytherapy making the treatment source able to ﬁt into needles among other
factors. The average photon energy is 380 keV.
GammaMed 12i hdr source This source type is used in GammaMed 12i
hdr afterloader. It has an active length of 3.4 mm, active diameter of 0.6 mm,
total diameter 1.1 mm and the distance from active end to tip is 0.86 mm. The
encapsulation is stainless steel [6]. The GammaMed 12i hdr source is outlined in
ﬁgure 6. Dosimetric evaluation of this source is presented in Ballester [16].
Figure 6: Mechanical design of the GammaMed 12i hdr source. All dimensions
are in mm. [16].
Nucletron hdr classic This source type (ﬁgure 7) is used in the MicroSe-
lectron hdr afterloader. The active length is 3.5 mm, active diameter 0.6 mm,
total diameter 1.1 mm and the distance from active end to top is 0.35 mm. The
encapsulation is stainless steel [6]. A dose rate table is presented in Williamson
and Lie, among others [17].
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Figure 7: Mechanical design of the Nucletron hdr classic source [17].
The mechanical design of the GammaMed source is similar to the classic Nu-
cletron source, except for a diﬀerence in distance from the active end to tip. This
diﬀerence is 0.5 mm. The dose distribution from the Nucletron source and Gam-
maMed source are compatible, with exceptions at angles less than 20◦ towards the
steel cable end. Here the diﬀerences are said to range from 5-8%. The diﬀerences
may be due to diﬀerent densities in the cables [6].
According to Williamson and Li, the dose rate distribution reported for the
Nucletron source should be applicable to the GammaMed source [17]. In Ballester
they concluded that there was good agreement between the two dose distributions,
except for points near the source. For these points the diﬀerences ranged from 5
to 25%. Diﬀerences were also found along the cable. Here the dose rate diﬀerences
were up to 10% showing the inﬂuence of the cable [16].
2.2.2 Ionization chamber
An ionization chamber can be used for measuring the amount of ionizing radia-
tion. The chamber is an instrument constructed to measure the number of ions,
generated by the radiation, within a medium. It consists of a gasﬁlled enclosure
with two electrodes between which a voltage is applied. The radiation interac-
tions ionize the gas, and the electric ﬁeld causes movement of the electric charges
towards the electrode of opposite sign. This creates an accumulated charge that
can be measured with an electrometer [18].
An ionization chamber is used to ensure that the dose delivered from a therapy
unit is as intended. The chamber is connected to an electrometer that display the
collected charge. A calibration factor is required converting the charge to dose
rate.
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Farmer chamber Multiple designs of ionization chambers have been developed
for use in diﬀerent situations. In this study a Farmer chamber was used for
measuring the radiation dose from the GammeMed source. The Farmer chamber
is a common design of cylindrical chamber for radiotherapy. The cylindrical outer
wall acts as one of the electrodes and is made of graphite. The other electrode is a
thin aluminum central rod. Most cylindrical chambers are supplied with a build-
up cap, but this is not used when measuring in a phantom. These chambers can
be used for both relative and absolute dose measurements, but for the latter case
a calibration factor is necessary in order to determine the dose rate in absolute
units at the reference point in water [18]. An illustration of the farmer chamber
is shown in ﬁgure 8.
Figure 8: An illustration of the farmer chamber. All dimensions are in mm [18].
2.2.3 Electrometer
To measure the charge from the ionization chamber, an electrometer can be used.
In most cases the electrometer includes a voltage supply and a display unit.
Most electrometers are based on negative-feedback operational ampliﬁers. The
principle of such an electrometer is shown in ﬁgure 9. Negative feedback means
that some or all of the ampliﬁers output is fed back to its negative input. Total
feedback results in a gain of unity.
As seen in the ﬁgure, the negative input of the operational ampliﬁer is con-
nected to the chamber collection electrode and the positive input to a polarizing
voltage or to the case ground. If then a capacitor or a resistor is connected in the
feedback loop, the voltage measured at the output of the ampliﬁer is proportional
to the charge collected, and is equal to the voltage across the capacitor or resistor.
When a capacitor C is placed in the feedback loop and the voltage measured
across the capacitor is V, then the charge collected, Q, is equal to CV. If instead
a resistor R is placed in the loop, the voltage, V, measured across the resistor
allows the current, I, to be determined as V/R [18].
2.2.4 Calculation from charge to dose rate in water
It was of interest to measure the dose from the source used at St. Olavs Hospital
to see how well the measurements correlate with the similar calculated values
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Figure 9: The principle of negative-feedback operational ampliﬁer electrometer
[18].
given in two diﬀerent treatment planning systems.
An ionization chamber was used to perform the measurements, and an elec-
trometer was used to measure the charge. Equation (2) is used to calculate from
the charge to the absorbed dose in water, DW,Q, for radiation quality Q [18].
DW,Q = MQNS,Q0f
D,S
Q,Q0
(2)
Here NS,Q0 is the calibration factor in terms of a radiation quantity, S, in
a beam of a standard quality, Q0. This calibration factor is provided with the
chamber. MQ is the electrometer reading, suitably corrected in the user's beam.
fD,SQ,Q0 is any overall correction factor necessary to convert both from the calibration
quantity, S, to dose, D, and from the calibration quality, Q0, to the user's quality,
Q [18].
Correction factors To calculate the correct dose rate in water, correction fac-
tors have to be applied. iaea tecdoc [19] describes methods for obtaining the
correction factors in brachytherapy.
The polarity eﬀect comes from reversing the polarity on an ionization chamber.
This means making the central node +V with respect to the wall and then change
it to -V. In this case the correction factor for this eﬀect is 1, since the eﬀect is
practically negligible for high-energy photons.
Charge will be detected that does not stem from the source itself, and this
noise should be removed. For correction, charge detected was accumulated with-
out the source in place, and this value was subtracted from the measurements.
The charge measured by an ionization chamber is dependent on pressure,
temperature and humidity. When calibrating the chamber, the calibration factor
must be given for stated reference values of these parameters. Most calibrations
factors refer to T0 = 20 ◦C and P0 = 101.3 kPa. A correction factor should be
applied to convert the measured charge to the reference conditions used for the
ionization calibration. Calculation of this correction factor, kTP , is shown in
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equation 3. Here P0 and T0 are the reference values and P and T is the actual
pressure and temperature when performing the measurements.
kTP =
(273.2 + T )
(273.2 + T0)
P0
P
(3)
Calibrating the chamber is done without humidity correction, but the rela-
tive humidity during calibration is controlled within the range of 45-55%. The
calibration factor applies for relative humidity around 50%, but in practice no
correction factor is required from 20 to 70%. Therefore the correction factor for
humidity, khum, is equal to 1.
The recombination of positive and negative ions within the air cavity reduces
the amount of charge collected. At St. Olavs Hospital this correction factor,
krecomb, has been measured to be equal to 1.
A calibration factor, Nk, for air kerma rate is provided for the ionization
chamber. This factor applies when the temperature, pressure and humidity is as
stated previously.
Stopping power is deﬁned as average energy loss per unit distance, Scol/ρ.
This is dependent of the medium. Determination of absorbed dose in a medium
using an ionization chamber is based on a principle (Bragg-Gray) relating the
absorbed dose at a point in the medium (water) to the mean absorbed dose in the
detector (air) through a proportionality factor: ratio of mass (collision) stopping
power, Sw,air. For 192Ir the stopping power ratio is 1.11.
For comparison between measurements with diﬀerent radiation/accumulation
time, it is more convenient to discuss dose rate than dose, and therefore the
radiation time, t(s), is also included in the formula.
Equation (2) can then be written as shown in equation (4), in terms of dose
rate, D˙W,Q.
D˙W,Q =
MQ
t
NKSw,airkpolkTPkrecomkhum, (4)
The unit is Gy/s and MQ is corrected for noise and polarity [18] [19].
To be able to compare the dose rate with the treatment planning system,
or measurements done on diﬀerent days, it is important to include the date of
the actual measurements or treatment planning, since the source decays. It is
common to calculate the dose rate as if the measurements where done on the
calibration date, and a decay factor is then needed. This is shown in equation
(5).
Fdecay = e
−ln2 · t/t 1
2 , (5)
where t 1
2
is the half-life of the source and t is the time since the calibration
date. Equation (6) then gives the dose rate, if it were to be measured on the
calibration date. A decay table for the source is ofteen included when a new
source is delivered.
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D˙W,Q(0) =
D˙W,Q(t)
Fdecay
(6)
A calculation example of charge to dose rate in water is shown in appendix A.
2.3 3D treatment planning
2.3.1 Formalism of Task Group No 43 (TG-43)
Treatment planning and dosimetry has not developed at the same rate for brachy-
therapy as for that of external beam radiotherapy. The same relatively simple
algorithms and calculation procedures have been in use for many years, not having
any accurate dosimetry system available. Recently there has been some new
developments associated with brachytherapy treatment. Increased availability of
ct scan data, use of mr-images for volume deﬁnition and the use of Monte Carlo
methods for dose calculation are some examples. These new developments have
led to an increased interest for improved accuracy of brachytherapy dosimetry [6].
The Radiation Therapy committee of the American Association of Physicists
in Medicine (aapm) formed Task Group No 43 (tg-43) in order to review the
diﬀerent publications on the dosimetry of interstitial brachytherapy sources. They
recommend a dosimetry protocol including a formalism for dose calculation and
a dataset for the values of dosimetry parameters [6] [20].
Traditionally, the dose rate, D˙(r), at a distance r from an interstitial brachyther-
apy source was calculated using a point-source approximation. One problem with
the older protocols is that they are based on photon ﬂuence around the source in
free space, not considering a scattering medium around the source (e.g. a patient)
when calculating the dose distribution. In the recommended formalism this prob-
lem is solved by the use of measured dose distribution produced by a source in a
water equivalent medium.
The recommended formalism allows for two-dimensional dose calculations
around cylindrical symmetrical sources, whereas the old protocol could only han-
dle one-dimensional point isotropic sources. The geometry of the formalism is
deﬁned in a polar coordinate system, with its origin in the source center and the
angular origin in the longitudinal axis of the source. This is visualized in ﬁgure
10.
The dose at a point P(r,θ) in ﬁgure 10 can then be expressed as shown in
equation (7).
D(r, θ) = SkΛt
G(r, θ)
G(r0, θ0)
g(r)F (r, θ) (7)
Here r is the radial distance from the center of the source and θ is the polar
angle with respect to the longitudinal axis. The reference point, r0θ0, is located
at r0 = 1 cm, θ0 = pi2 .
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Figure 10: Illustration of the geometry assumed in the formalism recommended by
TG-43. P(r0, θ0) is the reference point [20].
Sk is air kerma strength, deﬁned as the product of air kerma rate and the
square of the calibration distance, with units µGy ·h−1m2. aapm recommends
that sources should be speciﬁed in terms of Sk [21].
Further, Λ is the dose rate constant and t is the exposure time. G(r, θ) is the
geometry factor accounting for the dependence of photon ﬂuence around a source
in free space. F (r, θ) is the anisotropy function and accounts for anisotropy of
dose distribution produced by a source in a scattering medium. g(r) is the radial
dose function that includes the distance dependence of absorption and scatter in
water along the transversal axis of the source.
The formalism recommended by this group has found broad acceptance and
is now commonly used to describe the dose distribution of new and existing
brachytherapy sources. It is the basis of many treatment planning systems, i.a.
Masterplan and Plato used in this study.
2.3.2 3D treatment planning systems
A 3D treatment planning system can import ct and mr-images of a patient. In
the images it is possible to see and thereby delineate anatomical structures of
interest. The applicator can also be visualized in the image. Dose distribution is
calculated without considering the applicator extent, but the applicator position
is delineated in the image to deﬁne where the source can be positioned.
From the information visualized it is possible to manually create an optimized
treatment plan, adjusting source positions and dwell time in each position. The
system can then calculate the doses received in diﬀerent volumes.
Plato planning system The treatment planning system currently used at
St. Olavs Hospital for creating treatment plans for brachytherapy of cervical can-
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cer is Plato planning system (Plato Brachytherapy Planning System v. 14.2.6)
[22]. This has been in use since 2005.
Masterplan Since 2004 Masterplan (Oncentra Masterplan (Nucletron) v. 1.5)
has been used when making treatment plans for external radiotherapy at St. Olavs
Hospital, and recently a module for brachytherapy has become available [22]. Un-
til now Masterplan has been used during brachytherapy only to draw the struc-
tures of interest, before exporting the images to Plato for further treatment plan-
ning. Now it was of interest to evaluate the possibility for carrying out all parts
of brachytherapy treatment planning in Masterplan. A screen shot of Masterplan
in the brachytherapy module is shown in ﬁgure 11.
Figure 11: A screen shot of Masterplan in the module used for brachytherapy
planning
2.3.3 Dose Volume Histogram
To evaluate dose to target, normal tissue and oars, values of interest can be
extracted from dose volume histograms (dvhs) of 3D treatment plans. A dvh
shows how much dose diﬀerent volumes of an organ receives. An example of a
dvh is shown in ﬁgure 12. For comparing the overall dose delivery to a number of
diﬀerent structures of one particular treatment plan, the cumulative histograms
for each of these structures are useful [3]. The volume receiving a given dose,
minimum dose in a given volume and dose to the oars can be found from dvhs.
Finding parameters of interest The volume of ctv receiving the presribed
dose (in this study 5 Gy), ctv V100, is found from the dvh as shown in ﬁgure
12.
The minimum dose in 90% of the volume, ctv D90, is found by calculating
90% of the total volume of ctv, and then using the graph to ﬁnd the minimum
dose in this volume.
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Figure 12: Example of a cumulative dvh. The y-axis represents the volume (cm3)
and the x-axis represents the dose (Gy). The pink graph is the ctv, the green
graphs are the three oars and the blue graphs are the non-tissue material within
and outside ctv. In the outlined square ctv V100 is read out. The external
contour is not visualized in this dvh.
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The normal tissue receiving the prescribed dose, ext V100, is found using the
graph for the external contour, ﬁnding the volume receiving the prescribed dose.
Then ctv V100 is subtracted to obtain the volume of the normal tissue.
2.3.4 Inverse planning simulated annealing (IPSA)
Simulated annealing is a method for locating a good approximation to the global
minimum of a given function in a large search space, often used when the search
space is discrete. The goal should be to ﬁnd an acceptable solution in a ﬁxed
amount of time [23].
Inverse planning simulated annealing (ipsa) make use of the simulated an-
nealing algorithm to ﬁnd a good treatment plan for a given patient based on a
set of dose constraints.
In order for ipsa to work, structures of interest must be delineated, such as
target volumes and organs at risk. Then dose constraints and weighting factors
can be given to each structure. Dose constraints can be given as both volume and
surface restrictions to the structure.
In ﬁgure 13, the ipsa dialog box in Masterplan is shown. Here minimum
and maximum dose to either volume or surface of the structures and appurtenant
weighting factors are set. The example in the ﬁgure is shown in table 1. ipsa
searches for the best possible solution that conforms to the given dose constraints
by making diﬀerent solutions by adjusting the dwell times in each position. The
dwell positions are automatically generated by ipsa.
Figure 13: The dialog box for ipsa in Masterplan.
Table 1: An example of a set of dose constraints with appurtenant weighting
factors.
Dosemin Weight Dosemax Weight
Target surface 5 100 6.0 15
Bladder surface 5.7 100
Rectum surface 4.3 100
Sigmoid surface 4.3 100
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The weighting factor (Mmin, Mmax) sets the slope of the penalty function. If
dose constraints are violated, the penalty will increase at the given rate. This is
visualized in ﬁgure 14.
Figure 14: Allowable range of dose and an assigned penalty for violating that
range. Dmin and Dmax are the minimum and maximum dose, and Mmin and
Mmax are the slopes of the penalty for violating minimum and maximum dose
constraints, respectively [5].
The best treatment plan will be the plan with the least amount of penalty
[5]. For ipsa to ﬁnd this treatment plan, the dose constraints are described
mathematically.
The total dose, Di, at point i is calculated by summing the dose contribution
from all source positions, j, with their respective dwell time, tj , as shown in
equation (8). dij represent the dose rate at point i from the source position j.
Di =
∑
j
dij · tj (8)
The penalty value, Wi, for each dose point generated by the algorithm can
then be found as shown in equation (9) .
Wi =

Mmin|Di −Dmin| if Di < Dmin
Mmax|Di −Dmax| if Di > Dmax
0 if Dmin ≤ Di ≤ Dmax
(9)
The sum of penalty values over all dose points leads to the global penalty
known as the cost function, shown in equation (10). The sum is applied over all
dose points, i, of each type, m, (volume or surface) for each deﬁned volume, z.
This determines the quality of dose distribution. A smaller global penalty value
means that the treatment plan is closer to ideal dose distribution [24].
CF =
1
Nvolumes
∑
z
(
1
2
∑
m
(
1
Npointsmz
∑
i
Wimz(tj)
))
(10)
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The ipsa program is combination of two parts. A user-to-computer trans-
lator that gathers the anatomic dose constraints given by the physician and an
optimization engine that ﬁnds the best solution to fulﬁll the dose constraints.
2.4 Evaluation of treatment plans
Generally a 3D treatment plan for radiotherapy can be evaluated by means of
indexes containing information about how well the target volume is covered, to
which level normal tissue is irradiated and how well the given tolerance limit of
the oars is kept. It is also of interest to be able to distinguish between these
three factors. For brachytherapy of cervical cancer it is diﬃcult to include the
bladder, rectum and sigmoid in such an index [1]. Use of 2D plots is therefore
suggested with evaluation indexes versus the minimum dose in the 2 cm3 volume
receiving the highest dose (oarD2 cm3). This plot makes it possible to include the
oars and to gain more information on the quality of the treatment plan.
In this study, three indexes have been used for evaluation, tc (target cover-
age), coin (conformal index) and coin(weight) (coin including a weighting factor
for the irradiated normal tissue to emphasize the target coverage. The weighting
factor equals 0.5 in this study). All indexes give values between 0 and 1, where 1
is the best possible value. The three indexes are shown in equation (11) [25], (12)
[26] and (13) [27], a deﬁnition of the volumes used is shown in ﬁgure 15 and the
abbreviations are listed below.
Figure 15: Illustration of the volumes used in the indexes.
CTV Clinical target volume (cm3)
CTVref Clinical target volume receiving the prescribed dose or more (cm3)
Vref Volume receiving the prescribed dose or more (cm3)
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TC =
CTVref
CTV
(11)
COIN =
CTVref
CTV
· CTVref
Vref
(12)
COIN(weight) =
CTVref
CTV
·
(
1− 0.5
(
Vref − CTVref
Vref
))
(13)
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3 Methods and materials
3.1 Brachytherapy of cervical cancer
3.1.1 Treatment
At St. Olavs Hospital icbt is administered with a remote afterloading machine
(GammaMed12i, see ﬁgure 16). GammaMed afterloader can be connected to an
applicator placed in the treatment position near the target volume of the pa-
tient. Before brachytherapy of cervical cancer, the applicator is ﬁtted in place
in the uterus/vagina region during anesthesia by the physician, and the position
is maintained by vaginal packing. The applicator used is a Titanium Fletcher
style applicator with ﬂexible geometry from Varian medical system. The source
is placed in the applicator by the remote afterloading machine after the personnel
has left the treatment room. The source used is a 192Iridium source with a di-
ameter less than 1 mm. It is used as a stepping source, meaning that it is placed
in the deﬁned source positions for a certain amount of time (dwell time). The
individual source positions and dwell times are speciﬁed by the treatment plan.
Figure 16: The remote afterloading machine used at St. Olavs Hospital, Gam-
maMed 12i hdr.
The cervical cancer patients included in this study received external radiation
therapy combined with brachytherapy of the cervix area as a boost. From the
external treatment the patients received 50 Gy in 2 Gy fractions. For the icbt
treatment, the patients were treated with 4 fractions, 5 Gy per fraction. 11
patients treated at St. Olavs Hospital between 2007 and 2009 are the basis of the
retrospective evaluation in this study. The use of the data have been approved
by the patients and the ethical committee at St. Olavs Hospital.
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3.1.2 Regions of interest (roi)
For each fraction of brachytherapy, mr-images are taken with the applicator in-
serted in the cervix area (mr-machine: Siemens Avanto 1.5 T, resolution equals
1 mm). The images are transferred to the dose planning system, Oncentra Mas-
terplan version 1.5 (Nucletron). The following regions of interest are delineated
in each of the images.
• Target volume
• oars (Bladder, rectum and sigmoid)
• Non-tissue material (Applicator and vaginal packing)
• Body contour is automatically drawn in Masterplan
The physician delineates a target volume deﬁned as the clinical target volume
(ctv) including the tumor, cervix, inﬁltration of parametrium, upper part of
vagina, lower part of uterus and preferably the whole endometrium. The surface
of this volume should receive 5 Gy on average. The physician allows for original
tumor spread, and the volume delineated is a modiﬁcation of the deﬁnition of
hr-ctv from gec-estro.
The rectum and the sigmoid are drawn in the mr-slices where the target
volumes are drawn and in a few slices cranially and caudally of these. Therefore
the detected total volumes of the rectum and the sigmoid in the dose planning
system are smaller than the total volumes of these organs. The whole volume of
the bladder is drawn. Before treatment the bladder is drained, and then ﬁlled
with 100 ml 0.9% NaCl. The main reason for ﬁlling the bladder is that most of
the bladder wall should be moved away from the target volume, thereby reducing
the dose to a larger part of the bladder wall. If the bladder had been empty, the
whole bladder wall would be closer to the target volume and thereby receive more
radiation.
The non-tissue material includes the volume of the applicator/ovoids and the
vaginal packing that is placed to maintain the position of the applicator. One
structure is drawn for the non-tissue material lying inside the delineated target
volume, and one for the volume outside. The volume of the non-tissue material
has been excluded in all other volumes containing this, since these regions are
of no clinical relevance. Removing the non-tissue material from the target- and
normal tissue volumes makes the dose and volume values more clinical relevant,
and more comparable to similar published data [13].
The body contour is used to obtain the total volume encompassed by the 100%
isodose and other values concerning the adjacent normal tissue.
3.1.3 Treatment planning
Currently treatment planning is performed in the dose planning system Plato
Brachytherapy Planning System v.14.2.6 (Plato) at St. Olavs Hospital (chapter
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2.3.2). This system can import both ct and mr-images with the delineated
structures.
The structures of interest are delineated in Masterplan, and then exported
to Plato where the applicator and the source positions are deﬁned. The uterine
applicator and the two ovoids are reconstructed separately in the images. Re-
construction of the applicator in mr-images have been tested using phantoms at
St. Olavs Hospital, and is accepted. Then a set of source positions in the ap-
plicators are deﬁned. The distance between each possible source position in the
applicators is 5 mm. The source positions lying inside the ctv are chosen to be
active. A set of equally spaced dose points is also deﬁned, lying on the surface of
the target volume. The deﬁned applicator and source positions are shown in ﬁg-
ure 17. The computer calculates the dwell times in each source position, making
the mean dose to the dose points equal to the reference dose. The isodose curves
are visualized in the mr-images and dose to diﬀerent volumes can be extracted
from dvhs.
Figure 17: Applicator and source positions visualized in Plato planning system
(frontal view). The red structure is the delineated target volume.
As discussed in chapter 2.1.6 the diﬀerent oars have speciﬁc limits for how
much radiation they tolerate. These are not taken into consideration by the
Plato planning system, but adaption is possible by manually altering dwell times
and source positions. The tolerance dose per fraction used in the treatment at
St. Olavs Hospital are calculated from the biological equivalent dose as shown in
appendix B and are given in table 2. These calculations apply when 50 Gy is
given by external radiation and icbt is given in 4 fractions. The tolerance dose
recommended by gec-estro for the total treatment has been used.
3.2 Comparison of dose calculations in Masterplan and Plato
To start the assessment on whether or not it is possible to use Masterplan instead
of Plato for brachytherapy planning using the actual applicators, a comparison of
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Table 2: The tolerance limits per fraction for oarD2 cm3 .
OAR Tolerance limit per fraction
(Gy)
Bladder 5.7
Rectum 4.3
Sigmoid 4.3
the calculated dose distribution from the two programs was performed. Identical
catheters were created in each of the computer programs, and the dose values at
predeﬁned points were read out and compared.
The diﬀerence (absolute values) between the doses calculated by Masterplan
and Plato in each point is given as percentages of the dose calculated by Plato
at that point. During the work, it was evident that this diﬀerence was larger in
some regions than in others. In order to cover more precisely the areas with large
errors, more points were read out in these regions. The diﬀerence in percentages
of the calculated doses were then plotted, and the plots are shown in chapter 4.1.
The coordinate system used in the plots is shown in ﬁgure 18.
(a) Point source (b) Straight catheter with 11 source posi-
tions
Figure 18: The coordinate system used for the points compared in Plato and Mas-
terplan. Only points for positive x have been used, since the treatment planning
systems simulate a cylindrical symmetrical source.
Measurements were performed simulating both a point source and a straight
catheter with 11 source positions with equal center-center distance of 5 mm, and
equal dwell times. The point source was situated in origo with the longitudinal
direction of the source positioned along the z-axis. For the catheter, the points
were evenly distributed between (0,0) and (0,50) mm.
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3.3 Measurements of the GammaMed 12i hdr source
Measurements of the dose rate from the GammaMed source were performed for
comparison with the dose calculations from Masterplan and Plato.
3.3.1 Measurement set-up
The measurement set-up is shown in ﬁgure 19 and included:
• Water phantom with a steering unit (Blue phantom and the software Om-
niPro accept (iba dosimetry))
• Ionization chamber (Farmer chamber FC65-G, calibrated for Iridium, Nk =
43.8 · 106 Gy/C)
• GammaMed 12i hdr source and afterloader (the treatment unit at St. Olavs
Hospital)
• 4 diﬀerent catheters
• Electrometer (Scanditronix Wellöfer Dose 1)
Figure 19: Illustration of the measurement set-up.
The ionization chamber was placed as shown in ﬁgure 20(a). The point source
was positioned in origo in the coordinate system shown in ﬁgure 20(b), which also
shows some of the points measured. All points measured are given in table 3.
Measurements were performed with the source placed in four diﬀerent catheters:
One catheter made of nylon (nylon), one being the Fletcher type ovoid catheter
without a cap (ovoid) and two versions of the Fletcher type uterine catheter, one
straight (StSt(straight)) and one slightly bent (StSt(bent)), both made of stainless
steel. A picture of the diﬀerent catheters used is shown in ﬁgure 21.
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(a) (b)
Figure 20: Illustration of the positioning of the ionization chamber (a) and the
points measured (b).
Table 3: The points measured ((x,z) in the coordinate system in ﬁgure 20(b))
x-axis z-axis
(mm) (mm)
(12.5,0) (0,20)
(17.5,0) (0,25)
(22.5,0) (0,30)
(32.5,0) (0,40)
(52.5,0) (0,60)
(72.5,0) (0,80)
(92.5,0) (0,100)
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Figure 21: The four diﬀerent catheters used when measuring the source. From the
top: StSt(straight), nylon, ovoid and StSt(bent).
3.3.2 Measurement procedure
To be able to place the center of the source in the position deﬁned as origo for
every catheter, it was necessary to ﬁnd the oﬀset, i.e. distance from the tip of
the catheter to center of the source placed in the position nearest to the tip. To
ﬁnd this oﬀset the catheters were attached to a ﬁlm (Gafchromic R©EBT). The
tip end of the applicator was marked on the ﬁlm, and the ﬁlm was radiated for
10 s. The distance from where the dose maximum was seen on the ﬁlm to the
marked tip end was measured. The oﬀset was found to be 4 mm for nylon, 5 mm
for StSt(bent), 5 mm for StSt(straight) and 10.5 mm for ovoid.
For the measurements the GammaMed 12i hdr source and remote afterloader
was used. The catheter was placed in the water phantom and held in place by a
bar positioned across the water phantom. The ionization chamber was placed in
the steering unit and positioned with the center in the ﬁrst point to be measured.
Then it was connected to the electrometer. The catheter was connected to the
afterloader, and after leaving the room, the source was placed in the catheter,
radiating the ionization chamber. The charge detected was accumulated over a
certain amount of time and displayed by the electrometer.
After measuring in one position, the ionization chamber was moved by the
steering unit to the next position to be measured. This was repeated until all
positions had been measured. For each position the accumulated charge was
measured twice, and the average was used for further calculation. These mea-
surements were performed for all four catheters.
The measurements were performed on diﬀerent days. The accumulation time
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for the ﬁrst day was 60 s and for the second day 90 s.
An accumulation of charge detected was performed when the set-up was com-
plete, without the source in place to ﬁnd the noise. This was found to be 5.3 pC
for 60 s and 8.6 pC for 90 s.
To be able to calculate the correct dose rate, actual temperature and pressure
were measured both days.
The dose values calculated by Masterplan and Plato for the same positions as
the ones measured were found simulating a point source in origo at the calibration
date. The dwell time for the point source was read out and included in the
calculations.
The measurements were converted from charge to dose rate (chapter 2.2.4)
and the dose given in Masterplan and Plato were converted to dose rate. The
values were plotted in excel, and are shown in chapter 4.2.
3.4 Comparison of treatment plans
3.4.1 Treatment plans
Diﬀerent ways to create treatment plans are available in Masterplan. The algo-
rithm, ipsa, is evaluated in this study.
Currently at St. Olavs Hospital, doses to oars are not taken into consideration
by the treatment planning program (Plato), and manual alteration of the dwell
times to get a better dose distribution is time consuming. It is of interest to
reduce the time spent on manual alteration. Therefore ipsa was tested to see
if this algorithm, where dose restriction to oars can be set, can give a better
starting point for a treatment plan where less alteration is necessary.
Three ipsa plans with diﬀerent dose constraints, free to optimize dwell times,
and one plan with equal dwell times, where the dose was normalized to ctv, were
made retrospectively for 11 patients. The four treatment plans were evaluated to
see if one plan can give a better starting point than the others.
For treatment planning, the regions of interest had previously been delineated,
but the applicator needed to be reconstructed, i.e. possible source positions in
the applicator needed to be indicated. For the plan with equal dwell times, the
source positions also had to be deﬁned. These are evenly distributed (5 mm)
along the applicator within the ctv. ipsa automatically generates the source
positions within ctv, but adjustment of margins is possible in order to give ipsa
the possibility to place the source outside ctv. In this study, this margin was
set to 0, so all source position was placed inside ctv. Not all available source
positions are necessarily used by ipsa.
For the treatment plan with equal dwell times, 200 target points situated on
the target surface were calculated by Masterplan. Then the dose was normalized
the mean of these points. For the ipsa plans, three sets of dose constraints were
made, shown in table 4. To try to understand how ipsa generates a plan and
to ﬁnd solutions that can give a good starting point, diﬀerent ways of matching
constraints and weighting factors were tried on diﬀerent patients initially. From
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this trial and error method, three sets of dose constraints were suggested, and
these are the ones to be evaluated.
Table 4: Overview of dose constraints in the three diﬀerent ipsa plans
Plan ROI Surface Volume
Mmin Dmin Dmax Mmax Dmax Mmax
ipsa1 ctv 100 5 Gy 6 Gy 15
Bladder 5.7 Gy 100
Rectum 4.3 Gy 100
Sigmoid 4.3 Gy 100
ipsa2 ctv 100 5 Gy 6 Gy 15
Bladder 7.0 Gy 100
Rectum 5.3 Gy 100
Sigmoid 5.3 Gy 100
ipsa3 ctv 100 5 Gy 6 Gy 15 50 Gy 10
Bladder 5.7 Gy 100
Rectum 4.3 Gy 100
Sigmoid 4.3 Gy 100
ipsa1 At St. Olavs Hospital the delineated target should receive 5 Gy, so the
ﬁrst dose constraint sets minimum dose to the target surface to 5 Gy. The weight-
ing factor for this is set equal to 100. Then a maximum dose to the oar should be
included. At St. Olavs Hospital they operate with a tolerance limit for a certain
volume of the oar given in table 2. Setting a constraint for such a volume is not
possible in ipsa, therefore a maximum dose to the surface is used, i.e. no point
on the surface of the organ should receive the given dose. For ipsa1 this was
set to 5.7 Gy for the bladder and 4.3 Gy for the rectum and sigmoid. This is
conservative since these values represent the tolerance limit for a small volume of
the oar. From experimenting with ipsa it seemed that the maximum dose to the
organ surface sometimes was exceeded even though the dose constraints to the
organ was included. It is not of interest to repeatedly have too high doses to the
oars in the starting point for the treatment plan.
For some patients, all oars were situated at such distance from the target
volume that the tolerance limits to the oars were far from being exceeded. Then
the surrounding healthy tissue received quite high doses since no limiting fac-
tor for this was available. A maximum dose of 6 Gy to the target surface was
then considered. With a weighting factor of 15, this seemed to restrict the dose
distribution somewhat, without decreasing the target coverage considerably.
ipsa2 Since maximum dose to the surface of the oar in the previous suggestion
is conservative, a higher maximum dose was tested. For ipsa2 the maximum dose
to the surface of the oars is set to be 7.0 for the bladder and 5.3 for rectum and
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sigmoid (23% higher than for those given in ipsa1). The other dose constraints
are the same.
ipsa3 For some patients large diﬀerences in dwell times were observed. To avoid
this, a maximum dose to the target volume is tested. It seems like setting such
a maximum dose will force ipsa to use more source positions. This might reduce
the target coverage, so the weighting factor should not be large. A maximum
dose to the target volume of 50 Gy, with the weighting factor of 10 is suggested.
ipsa3 then equals ipsa1, with the addition of the maximum dose to target volume.
No manual alteration was done for any of the treatment plans.
3.4.2 Assessing the diﬀerent treatment plans
In this study, 11 patients that have been treated at St. Olavs Hospital are included.
The four treatment plans were made for the ﬁrst fraction for the patients, except
for one patient where the second fraction was used. The dvhs containing dose
information of ctv, oar, external contour and the two volumes of non-tissue
material were exported to a data base made for this purpose. Values of interest
were then extracted and calculated.
Statistical analysis In this study, four treatment plans are compared with
respect to each other. When more than two means are compared, anova (analysis
of variance) can be used. This is the same as a two-sample t-test, comparing more
means at once. When using ordinary pairwise comparison (several individual t-
tests), too many signiﬁcant diﬀerences between the sample means tend to be
found.
Between-group-variations and within-group-variations are compared in anova
to assess whether there is a diﬀerence in population mean. Thus by comparing
these two measures of variance with one another, true diﬀerences among the
underlying group population means can be detected. If the variations between
the sample mean is large, relative to the variation within the samples, it is likely
to detect a signiﬁcant diﬀerence among the sample means.
In this study tukey-intervals have been used for multiple comparison of dose
and volume parameters for the four treatment plans. A 95% conﬁdence interval
was used for all values, resulting in a P-value equal to 0.05 [28].
Assumptions The underlying assumptions when using anova are indepen-
dence, equality of variance and normality.
The observations (patients) within each sample (11 patients with one treat-
ment plan) should be independent and the samples should be independent of one
another. For this study the observations within each sample is independent from
the nature of the data, but since the samples include the same set of 11 patients,
they are not independent of each other. This is called repeated measures, and
anova can be used for these cases in the same way as for independent anova.
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Both equality of variance and the normality assumption was checked, using
Levene's test and Shapiro-Wilk test respectively. If there were no evidence against
these assumptions, comparison with anova could be performed. If there were ev-
idence against one of these assumptions, the values were evaluated more carefully,
and if necessary they were transformed. A logarithmic transformation was then
performed and the equality of variance- and normality assumptions were checked
again before executing the anova comparison and ﬁnding the level of signiﬁcance.
anova is robust to the normality assumption, and if the distribution is symmet-
rical and no gross outlier occur, transformation is not necessary. For one value it
was necessary to remove one patient, due to one gross outlier.
The data was statistically analyzed in the computer program R [29].
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4 Results
4.1 Comparison of dose calculations in Masterplan and Plato
It was of interest to compare doses calculated by Masterplan and Plato as one part
of the evaluation of whether or not it is possible to use Masterplan in stead of Plato
for treatment planning for the GammaMed source. Masterplan and Plato simualte
diﬀerent source types with slightly diﬀerent geometry, and therefore deviations in
the the two calculated dose distribution may occur.
A point source and 11 equally distributed source positions (catheter) was
simulated in both Masterplan and Plato, and the dose calculated in diﬀerent
points around the source were obtained. The diﬀerence in dose calculated by
Masterplan and Plato was found and is displayed in ﬁgure 22 and 23 as percentages
of the point dose calculated by Plato. Absolute values are used for this plot, but
both regions were the point dose calculated by Masterplan was higher than Plato
and opposite was found. The corresponding data ﬁle is shown in table 9 in
appendix C.
Point source There was one gross outlier in these measurements. Point (0,2)
had a deviation of 126%. If this point is included, it is diﬃcult to get any other
information from the plot, and the point is therefore removed. In ﬁgure 22(a) the
deviations in calculated dose around the point source between the two planning
systems is shown.
This ﬁgure shows that no large errors occur further away than 5 mm from
the source in x-direction. To get more information of the deviations around the
source, a plot is made for x ≤ 5 mm (ﬁgure 22(b)).
This plot shows that there is some deviation close to the source. More sur-
prisingly it also shows large deviation below the connector end of the source (x =
0, z ≤ 0).
In order to get more information about the distribution of the deviations,
points with errors greater than 20% were removed. All of these points were
situated close to the applicator or below the connector end. This leads to the plot
shown in ﬁgure 22(c).
From this plot it is possible to say that no deviations greater than 3% occur
further away than 4 mm from the points source (x-direction).
The deviations fall rapidly when moving in positive z-direction. No deviations
greater than 4% occur further away than 7 mm from the center of the source.
Catheter with 11 source positions Comparison of doses calculated by Mas-
terplan and Plato was also done simulating a straight catheter, with 11 equally
distributed source positions with equal dwell times within the catheter, with 5 mm
between each source position. The catheter was positioned on a line from (0,0)
to (0,50). There were one gross outlier, positioned at (0,52) with a deviation of
123.7%. This point was removed with the same argument as for the point source.
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(a) Deviation around the point source when one gross outlier was re-
moved.
(b) Deviation around the point source when x ≤ 5.
(c) Deviation around the point source when x ≤ 5 and the deviation
larger than 20% has been removed.
Figure 22: Deviations of doses calculated by Masterplan and Plato for a point
source. The colorbar represents the deviation in percentages. The source is placed
in (0,0), and the distribution of the deviations are shown in distance from the
source (mm).
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(a) Deviation around the catheter when one gross outlier was removed.
(b) Deviation around the catheter when x ≤ 5.
(c) Deviation around the catheter when x ≤ 5 and the deviation larger
than 20% has been removed.
Figure 23: Deviation of doses calculated by Masterplan and Plato simulating a
catheter. The colorbar represents the deviations in percentages. The catheter is
places from (0,0) to (0,50) with 5 mm between each source position. The distri-
bution of the deviations are shown in distance from the catheter.
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The deviation between Masterplan and Plato for this case is shown in ﬁgure
23(a). From this plot it is possible to see that there are no large deviations more
than 5 mm from the catheter in x-direction. The closer one get, the larger the
errors, but it is diﬃcult to read out any information of the distribution of the
deviations close to the source. Therefore, a plot is made for x ≤ 5 mm (ﬁgure
23(b)).
It is evident that there are large errors close to the catheter and below the
catheter in the connector end also for this case. To get more information of the
deviations, the errors above 20% were removed. The result is shown in ﬁgure
23(c).
From this plot it is possible to say that no deviations larger than 4% occur
further away than 4 mm from the catheter (x-direction).
The deviations fall rapidly in positive z-direction above the tip end. No de-
viations larger than 4% occur further away than 7 mm from the source center in
the position closest to the tip end.
4.2 Measurements of the GammaMed source and comparison
with Masterplan and Plato
It is of interest to measure the dose rate in points around a point source to
compare the dose rates with dose calculations from Masterplan and Plato. The
measurements were done with diﬀerent applicators with various shape and mate-
rial. The treatment planning systems calculate the dose distribution around the
source disregarding the applicator. The points where measurements were taken,
are given in chapter 3.3.1. The dose rate obtained from Masterplan and Plato are
shown in ﬁgure 24.
Figure 24: Dose rate calculated by Masterplan and Plato in diﬀerent distances
from the point source. Masterplan z and Plato z means that the points measured
are positioned along the z-axis. Masterplan x and Plato x are points lying along
the x-axis.
Calculation of dose rate values are similar for Masterplan and Plato in these
points, therefore the measurements were only compared with calculations from
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(a) Measurements of the points positioned along the x-axis.
(b) Measurements of the points positioned along the z-axis.
Figure 25: The dose rate from the measurements of the point source with diﬀerent
applicators and Masterplan as a function of distance from the source.
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(a)
(b)
Figure 26: Dose rate relative to mean dose rate from the measurements of the
point source with diﬀerent applicators and Masterplan, as a function of distance
from the source.
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Masterplan. The results from the measurements are plotted in ﬁgure 25.
According to the plot, there are diﬀerences in dose rate at speciﬁc points both
between the applicator types and between the measurements and calculations
from Masterplan. The diﬀerences are more evident closer to the source. The
measurements follow the same dose fall-oﬀ curve.
Dose rate relative to mean dose rate is plotted in ﬁgure 26. For the measure-
ments along the x-axis these plots show larger deviations closer to the source.
This also applies for the measurements in z-direction, even though it is not that
evident. The plots also show that the deviations also occurs for measurements
further away.
4.3 Comparison of treatment plans
4.3.1 Dose and volume means for the four treatment plans
The dose distribution from three diﬀerent plans created by ipsa (ipsa1, ipsa2 and
ipsa3) and one plan with equal dwell times (edt) for 11 patients are evaluated.
The results are shown in table 5. For most of the volume and dose means in the
table, the values from ipsa2 are the highest and the values from edt the lowest.
In general, the values from ipsa1 are higher than the values from ipsa3.
Table 5: The dose and volume means and standard deviations for parameters
extracted from dvh and calculated parameters for the four treatment plans.
EDT IPSA1 IPSA2 IPSA3
CTV D90 (Gy) 3.2 ± 0.5 4.6 ± 0.8 5.3 ± 0.8 4.2 ± 0.8
V100 (cm3) 78 ± 32 99 ± 40 108 ± 41 95 ± 33
V400 (cm3) 6.0 ± 3.0 9.0 ± 5.7 10.3 ± 6.2 6.3 ± 3.3
EXT V100 (cm3) 19 ± 9.8 48 ± 29 71 ± 36 32 ± 9.2
OARD2cm3 Bladder (Gy) 5.2 ± 0.9 5.4 ± 0.7 5.9 ± 0.6 5.1 ± 0.4
Rectum (Gy) 2.6 ± 0.7 3.4 ± 0.7 3.7 ± 0.8 3.2 ± 0.6
Sigmoid (Gy) 3.5 ± 0.9 4.3 ± 0.7 4.9 ± 0.8 4.2 ± 0.7
Indexes TC 0.66 ± 0.07 0.84 ± 0.11 0.92 ± 0.06 0.81 ± 0.09
COIN 0.54 ± 0.08 0.57 ± 0.09 0.56 ± 0.07 0.60 ± 0.07
COIN(weight) 0.60 ± 0.07 0.70 ± 0.09 0.74 ± 0.05 0.71 ± 0.08
tc is 0.92 for ipsa2 which indicates satisfying coverage of target. For edt, tc
is 0.66, meaning that the target coverage for this plan on average is poor. Values
for tc for ipsa1 and ipsa3 are similar, being 0.84 and 0.81 respectively.
The average for bladderD2 cm3 and sigmoidD2 cm3 for ipsa2 is 5.9 Gy and
4.9 Gy respectively. This is more than the tolerance limit for these two oars.
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The normal tissue receiving the prescribed dose, ext V100, for ipsa2 is 71 cm3
for ipsa2, while 19 cm3 for edt.
Statistical analysis A larger minimum dose in 90% of the volume (ctv D90)
indicates better target coverage. For ctv D90 all three ipsa plans have signif-
icantly higher values than edt, and ipsa2 has signiﬁcantly higher values than
ipsa3. No signiﬁcant diﬀerence was found between the diﬀerent plans for ctv
V100 or ctv V400.
ext V100 is the volume of the normal tissue receiving the prescribed dose,
and this value should therefore be small. For ext V100 ipsa2 has signiﬁcantly
higher values than ipsa3, and both ipsa1 and ipsa2 have signiﬁcantly higher
values than edt.
Also for the oarD2 cm3 , a smaller value is better. For rectum and sigmoid the
dose evalutad is signiﬁcantly higher for ipsa2 than edt. For the bladder the only
signiﬁcant diﬀerence is found between ipsa2 and ipsa3, where ipsa2 has higher
values.
For the indexes evaluated, a higher value signify a better plan. All three
ipsa plans have signiﬁcantly larger values for tc than edt, and tc is signiﬁ-
cantly higher for ipsa2 than for ipsa3. No diﬀerence is found for coin. For
coin(weight), all ipsa plans have signiﬁcantly higher values than edt. The P-
values for these statements are given in appendix D.
4.3.2 coin(weight) vs. oar
coin(weight) have been plotted versus bladderD2 cm3 , rectumD2 cm3 and sigmoidD2 cm3 .
The plot for the bladder is shown in ﬁgure 27. The plots for the rectum and sig-
moid are found in appendix E.
Points to the right of the vertical line in the plot represent a plan where the
tolerance limit of the oar have been exceeded. The total mean of coin(weight)
for all four treatment plans is 0.69, and points above the horizontal line indicate
that coin(weight) for that plan is better than the average. Therefore, points in
the upper left square signify a better plan. These points have been counted, and
the results are given in table 6.
Table 6: Number of treatment plans situated in the upper left square.
EDT IPSA1 IPSA2 IPSA3
Bladder 1 (9%) 8 (73%) 4 (36%) 8 (73%)
Rectum 2 (18%) 8 (73%) 7 (64%) 8 (73%)
Sigmoid 1 (9%) 3 (27%) 2 (18%) 4 (36%)
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(a) IPSA1 (b) IPSA2
(c) IPSA3 (d) EDT
Figure 27: COIN(weight) versus minimum dose in the volume (2 cm3) receiving
the highest dose for the bladder (bladderD2 cm3). For points in the upper left square
coin(weight) is better than average and the constraints with respect to the oar
are fulﬁlled.
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4.3.3 oars
Number of plans where the tolerance limit have been exceeded is also summed up
from these plots. These numbers are shown in table 7.
Table 7: Number of treatment plans where the tolerance limit for the given oar
have been exceeded.
EDT IPSA1 IPSA2 IPSA3
Bladder 4 (36%) 1 (9%) 7 (64%) 0 (0%)
Rectum 0 (0%) 1 (9%) 3 (27%) 0 (0%)
Sigmoid 3 (27%) 6 (55%) 9 (82%) 4 (36%)
One or more oar 5 (45%) 6 (55%) 9 (82%) 4 (36%)
4.3.4 Exclution of non-tissue material
In all values compared previously, the non-tissue material have been excluded to
get a more representative evaluation. In table 8 some values have been calculated
both including and excluding the non-tissue material to see what the diﬀerences
is.
Table 8: The diﬀerence in means for values extracted from dvh when including
and excluding non-tissue material.
Including edt IPSA1 IPSA2 IPSA3
ctv D90 3.4 ± 0.6 4.8 ± 0.8 5.5 ± 0.8 4.4 ± 0.8
V100 104 ± 40 127 ± 47 137 ± 48 123 ± 40
V400 11 ± 5.7 16 ± 6.1 19 ± 7.0 13.6 ± 4.6
Indexes tc 0.70 ± 0.06 0.86 ± 0.09 0.93 ± 0.05 0.85 ± 0.07
coin 0.56 ± 0.09 0.59 ± 0.10 0.58 ± 0.09 0.61 ± 0.08
coin(weight) 0.63 ± 0.07 0.73 ± 0.09 0.76 ± 0.05 0.73 ± 0.07
Excluding edt IPSA1 IPSA2 IPSA3
ctv D90 3.2 ± 0.5 4.6 ± 0.8 5.3 ± 0.8 4.2 ± 0.8
V100 78 ± 32 99 ± 40 108 ± 41 95 ± 33
V400 6.0 ± 3.0 9.0 ± 5.7 10 ± 6.2 6.3 ± 3.3
Indexes tc 0.66 ± 0.07 0.84 ± 0.11 0.92 ± 0.06 0.81 ± 0.09
coin 0.54 ± 0.08 0.57 ± 0.09 0.56 ± 0.07 0.60 ± 0.07
coin(weight) 0.60 ± 0.07 0.70 ± 0.09 0.74 ± 0.05 0.71 ± 0.08
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5 Discussion
Dose calculations in Masterplan and Plato are based on absorbed dose in water,
and do not consider variations in density of the tissue. The irradiated area in
brachytherapy of cervical cancer consists mainly of soft tissue with high water
content. Therefore this simpliﬁcation does not lead to large dose diﬀerences when
calculating the dose in water instead of soft tissue.
5.1 Comparison of dose calculations in Masterplan and Plato
The feasibility of using the Nucletron source type in Masterplan for simulation of
the GammaMed source type used for treatment at St. Olavs Hospital is evaluated.
Since Plato planning system simulates the GammaMed source and Master-
plan simulates the Nucletron source, comparing the dose distribution calculated
by Plato and Masterplan will give information on how the dose distribution for
the two source types diﬀer. From ﬁgure 22 and 23 in chapter 4.1 diﬀerences in
calculated dose are evident. Some of the diﬀerences are large, and are found in
certain regions. It is important to evaluate these regions to see if these deviations
is of importance.
During the treatment routine, assumptions are made in delineation of regions
of interest and reconstruction of applicator. Small deviations in the calculations
may be accepted.
For the point source one calculated dose point, positioned (0,2) mm from the
center of the source, was removed from the plot. The deviation detected here was
126%. The uterine applicator has an extent of 3 mm in diameter and an oﬀset in
the tip end of 5 mm. The actual point would be positioned within the applicator.
Deviations in this region will be of no clinical relevance. Also for the 11 source
positions, a calculated dose point was removed (123.7% deviation). This point
(0,52) was 2 mm from the source center in the tip end, which is within the uterine
applicator, and of no clinical relevance.
Figure 22(a) and 23(a) show that the calculated dose deviations in a certain
distance from the source are 2-3% and can be accepted. To get more information
of the deviations found closer to the source, a plot was made for both the point
source and the 11 source positions where x ≤ 5 mm.
Large calculated dose deviations occur close to the source, and also below
the connector end (along the z-axis) where the deviation is still evident several
cm from the source center. According to Ballester [16], it is expected to ﬁnd
deviations in this region, but not as large as 30% as the plot indicates. In a clinical
situation of brachytherapy of cervical cancer these regions will consist of vaginal
packing and the applicator, i.e. deviations in this region is not relevant to the
target volume or oars. However, in other clinical situations than brachytherapy
of cervical cancer, this region could be of relevance.
For further evaluation of the deviations in dose distribution calculated by
Masterplan and Plato, all points with larger deviation than 20% were removed
from the data ﬁle for the plot. These were all positioned close to the source or
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close to the z-axis below the connector end, which is within the vaginal pack-
ing in brachytherapy of cervical cancer. Removing these points will give more
information in areas of greater clinical relevance.
As found in chapter 4.1 deviations larger than 3% and 4% (point source and
catheter respectively) are not found further away than 4 mm in x-direction. Since
the applicator has a certain extent, and the vaginal packing is situated below the
connector end, the points with larger deviation than 3-4% will be within or very
close to this non-tissue material and have no clinical relevance for brachytherapy
of cervical cancer. For the tip end, no large deviations are found further away
than 7 mm from the source center (z-direction). With an oﬀset of 5 mm, this will
be close to the uterine applicator.
Only the positioning of the points have been discussed, and even if these
are in regions with no clinical relevance, these points are situated within certain
volumes, such as ctv and adjacent normal tissue. In intracavitary brachytherapy,
dose fall-oﬀ is rapid, and doses close to the source are extremely high, making
mean dose to ctv an irrelevant parameter to measure. It is more common to
evaluate measures such as the volume receiving the prescribed dose or more for
target and normal tissue or minimum dose in a certain amount of the target.
These measures will not be aﬀected by the deviations close to the source, due to
the high dose in these points.
If evaluating volumes close to the uterine applicator, such as ctv V400, the
dose deviations might have a clinical eﬀect. Removing the non-tissue material
from the calculations will then be recommended, since most points with consid-
erable dose deviations are situated within this non-tissue material.
The dose deviations will not aﬀect the calculated dose for the oars, since
oars are at some distance from the uterine applicator. As previously discussed,
calculated dose deviations here are negligible.
Deviations between dose calculations fromMasterplan and Plato do not change
signiﬁcantly when calculating for several source positions instead of a point source.
Deviations are found along the catheter and below the connector end for the
catheter. For the point source deviations are found close to the source and below
the connector end. This is in good agreement with that found in Ballester [16].
From this evaluation, it seems that using Masterplan and the Nucletron source
type for simulating the GammaMed source will give reasonable results.
5.2 Dose measurements around the GammaMed source
Measurements of the dose rate from the GammaMed source were performed to
compare the dose distribution to dose rates calculated by Masterplan and Plato.
From ﬁgure 25 in chapter 4.2 it is possible to see that when the chamber is
positioned 30 cm or more from the source, the diﬀerent measurements and the
results from Masterplan are equal. This applies to both measurements along the
x-axis and z-axis. Closer, deviations are found.
Small errors in the measurement set-up is diﬃcult to avoid, particularly for
the ovoid and the Stainless Steel(bent), since these applicators are curved. In
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addition, the ionization chamber has a certain extent and the ﬁrst position for
measurement is positioned manually. Therefore 1-2 mm errors in the set-up is
expected.
The dose fall-oﬀ is extremely rapid for the 192Ir-source, e.g. the dose rate
values from Masterplan decrease from 300 to 100 Gy/h over 10 mm. Therefore
there was raised a question of how close (3D) to the point measured one could ﬁnd
similar values in Masterplan. A manually check was done. The average distance
to agreement, i.e. distance from original point for measurement to a point in
Masterplan with the same value, was found to be 2 mm. The deviations found
can therefore be a consequence of measurement set-up. Due to the high dose
fall-oﬀ close to the source, this eﬀect is more pronounced for the measurement
closer to the source.
According to the relative dose rate plots, deviations are found for all measure-
ments, but they increase towards the source. Errors in measurement set-up will
concern all measurements, but is more prominent when the dose fall-oﬀ is high.
Presumably the deviations detected come from errors in measurement set-up,
and large deviations between the dose rate calculated by the computer programs
and dose rate measured do not occur. Small deviations however would be diﬃ-
cult to detect. The calculated dose rate in Masterplan and Plato are within the
uncertainties of the measurements.
Eﬀect of using diﬀerent applicators Dose measurements with the source
placed in diﬀerent applicators (diﬀerence in shape, thickness and material) were
performed.
The measurements when using nylon and StSt(straight) applicators are simi-
lar. Due to the geometry of the applicators, the set-up for these two are probably
more precise than for ovoid and StSt(bent), and this would lead to more correct
measurements.
The lowest dose rate was found when using the ovoid applicator. The di-
ameter of this applicator is 5.9 mm in diameter, while the diameter of the other
applicators are 3 mm. The thickness of the applicator was not corrected for when
positioning the ionization chamber. Measurements are therefore taken approx-
imately 1.4 mm further away than for the other applicators. This can be the
reason for the lower measurements.
Dose measurements from StSt(bent) applicator are between StSt(straight) and
the ovoid. Positioning the ionization chamber correctly was diﬃcult for the bent
applicator.
The applicator material is not included in the dose calculations by Master-
plan and Plato. For dose calculations along the x-axis, Masterplan has the high-
est values. This is expected, since Masterplan does not include attenuation in
the applicator material. However, for the vertical values the measurements from
StSt(straight), StSt(bent) and nylon are higher. Dose distribution calculated by
Masterplan and Plato is not completely circular, but has the shape of an apple.
The measurements along the z-axis are in the region of the slight dip in the dose
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distribution in the connector end.
5.3 Comparison of diﬀerent treatment plans
The aim of curative radiotherapy is to achieve tumor control while avoiding serious
damage to surrounding structures. High target coverage often leads to more
irradiated normal tissue and larger dose to the oars, and a compromise between
these factors is often necessary. Creating dose distributions more conformal to
the target can give better target coverage without necessarily increasing the dose
to surrounding structures.
A typical case is shown in ﬁgure 28. From this ﬁgure it is evident that posi-
tioning of the oars determine the possibility for a satisfying target coverage.
Figure 28: mr-image (sagital view) of a patient with delineated structures, be-
fore creating the treatment plan. Due to the positioning of the surrounding oars
and the uniform shape of ctv, a plan with satisfying target coverage should be
achievable for this patient.
The treatment plans made by ipsa will not necessarily be satisfying for all
patients, even though oars are taken into consideration together with coverage
of the ctv. The plans must be carefully examined and alteration may still be
necessary [30]. The main goal for using this algorithm is to get a better starting
point, in order to save time when preparing the treatment plan. Adjustment of
the dose constraints for diﬀerent patients will be time consuming and diﬃcult.
A set of dose constraints that can be used for every patient should therefore be
found.
The mean values for target coverage, irradiated normal tissue and dose to oars
given by dvhs in table 5 diﬀer, but from the statistical analysis fewer signiﬁcant
diﬀerences are found. As mentioned, 11 patients are included in this study, and
for a better statistical analysis more patients would have been preferable. Even
so, with the signiﬁcant diﬀerences found, assessing the mean values and using the
plots in chapter 4.3.2, evaluation of the treatment plans can be done.
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A pattern for the mean values in the table is detected. For all values, with the
exception of coin and bladderD2 cm3 , the value from ipsa2 ≥ ipsa1 ≥ ipsa3 ≥
edt. This suggests that better target coverage also will lead to more irradiated
normal tissue and larger dose to the oars.
Target coverage Minimum dose in 90% of the target volume, ctv D90, the
volume of ctv that receives the prescribed dose, ctv V100 and the index tc are
all indicators of how well the target is covered. For these three factors ipsa2 has
the highest value, indicating that this plan leads to best target coverage. edt has
the lowest values and will give the poorest target coverage.
Normal tissue A high target coverage is desired, but often this correlates with
more dose to the surrounding normal tissue. ext V100 is the volume of normal
tissue receiving the dose prescribed for the target. ipsa2 has the highest value for
ext V100 and thus ipsa2 is the plan leading to most irradiated normal tissue.
According to ext V100, ipsa1 will irradiate more normal tissue than ipsa3 and
edt. Lowest amount of irradiated normal tissue is found when using edt.
oars In a treatment planning situation, it is usually the oars that limit the
target coverage. Dose to the oars are of great importance when assessing these
four treatment plans, because if the tolerance limit is exceeded, the plan must
be altered. Figure 29 shows a case where bladder will limit the target coverage.
Dwell times in the source position in close proximity to the bladder is forced to
be low, for not giving too high dose to this oar. This case will also probably
lead to inhomogeneities in dwell time values, discussed later in this chapter. For
a better target coverage, higher dwell time values will probably occur in the tip
end of the applicator to compensate for the lower dwell time values closer to the
bladder.
For both bladder and sigmoid the minimum dose in the 2 cm3 volume receiving
the highest dose (oarD2 cm3) is higher than accepted for ipsa2. Average doses
over the tolerance limit indicates that many plans will need adjustment. The
average of oarD2 cm3 is below the tolerance limit for the other plans. Since this
limit is absolute, no plan should exceed the tolerance limit for any of the oar.
The average alone is therefore not representative for evaluating the oars.
A more relevant way of evaluating the quality of a treatment plan when it
comes to the dose to oar, would be to examine how many of the treatment plans
that exceed the tolerance limit for oarD2 cm3 . 82% of the plans from ipsa2 exceed
the tolerance limit for one or more of the oars. ipsa3 has the lowest amount of
plans (36%) that need adjustment due to the oars (table 7). Surprisingly this
is better than edt, which is said to be the conservative plan. This suggest that
allowing the dwell time to conform to the shape of ctv will give possibilities for
a better target coverage as well as less dose to oars. This is visualized in ﬁgure
30.
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Figure 29: For this patient the bladder is positioned in a way limiting the target
coverage to be lowered. Dwell times in the lower part of ctv must be lowered not
to exceed the tolerance limit.
The dose constraints from ipsa1 are set in such a way that no points on the
surface should receive a higher dose than 5.7 Gy for the bladder and 4.3 Gy for
the rectum and sigmoid. These numbers are the tolerance limit for oarD2 cm3 ,
and not what should be the maximum dose to the surface. The maximum dose to
the surface was found when oarD2 cm3 was at the tolerance limit. This maximum
dose to the surface was approximately 120% of the tolerance limit for oarD2 cm3 ,
and is set as the dose constraints for oars in ipsa2. Therefore it is surprising
that this dose constraint repeatedly leads to too high doses for one or more of the
oars. It was also tried to set the weighting factor for the oar constraint to 200
when testing ipsa, but this led to little change in the results. Keeping the dose
constraints for oar low are therefore suggested. This seems to correlate with the
litterature, where they set the dose constraints for the surface of an oar in the
same range as the tolerance limit to the 2 cm3 volume [31] [32].
When reading out values for oars from the dvh, it is important to consider
continuity in the 2 cm3 volume. In a study like this, continuity of the high dose
area of the organ is assumed, but not necessarily the case. When obtaining the
dose in the 2 cm3 volume from the dvh, there is no guarantee that this volume is
continuous, and this method can lead to wrong conclusion when evaluating dose
to these organs. An example where this is evident is shown in ﬁgure 31.
A manual inspection was done to see if there were any cases where it was
clear that the 2 cm3 volume was not continuous. For two patients the sigmoid
had a shape like the one in ﬁgure 31 and the sigmoid was the limiting factor.
For this case the 2 cm3 volume is probably not continous. Restricting the dose
distribution due to this will then be incorrect. One more patient had a sigmoid
with the same shape, but here the dose to the sigmoid was far from the tolerance
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(a)
(b)
Figure 30: An illustration of the eﬀect of shaping the isodose lines, in order to get
better target coverage in addition to less dose to the oars.
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Figure 31: An example where it is evident that the 2 cm3 volume receiving the
highest dose will not be continuous.
limit. Then the plan would not be aﬀected by the misleading read out. For the
cases above it is clear that the volume is not continous, but for some cases it is
diﬃcult to see whether the volumes were continous or not.
Continuity is assumed, but not the case for all patients. International rec-
ommendation suggest that a part of an oar receiving high doses should have a
volume of 2 cm3 before bearing clinical relevance. A better target coverage could
have been achieved since a higher dose to the oar could have been given without
damaging the organ. For this study, all four treatment plans are made for the
same patients, so comparing these plans with respect to each other will still be
suﬃcient.
A worst case scenario is also assumed when calculating the tolerance limit per
fraction: It is the same region of the oar that receives the maximum dose for
every fraction.
Indexes All indexes used in this study have values between 0 and 1, where 1 is
the best possible value.
tc is an index giving information about how well the target is covered (equa-
tion (11)). This index has been discussed previously (target coverage). If the
oars are situated at a certain distance from the target, normal tissue might re-
ceive large radiation doses in order to improve target coverage. Therefore an
index including normal tissue in addition to target coverage has been suggested
[26]. coin is such an index (equation (12)).
ipsa3 has little irradiated normal tissue, and since it has better target coverage
than edt it will be the best starting point for a treatment plan according to coin.
Irradiated normal tissue is important to consider, but since three surrounding
organs are monitored in particular, target coverage is of greater importance and
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an index weighting target coverage and irradiated normal tissue equally can be
misleading. A modiﬁcation of coin has been suggested, where a weighting factor
is added to the term for normal tissue, emphasizing the target coverage. In this
study, the weighting factor has been set to 0.5 (equation (13)).
ipsa1 and ipsa3 have similar values for coin(weight). ipsa1 has the bet-
ter target coverage and ipsa3 has less irradiated normal tissue. According to
coin(weight), ipsa2 is the best treatment plan.
Inhomogeneous distribution of dwell time values An inhomogeneous dis-
tribution of dwell time values was detected. This is not desired, and can lead
to extremely high doses within ctv and for some cases outside ctv. An easily
available measure for inhomogeneities in dwell time values is diﬃcult to ﬁnd. High
dwell times in one source position will yield large doses around this point. ctv
V400 is the volume inside ctv receiving 400% of the prescribed dose. It may
therefore give an indication of inhomogeneities in dwell time values, and it is a
measure of the unwanted eﬀect resulting from these inhomogeneities. An example
where one plan with equal dwell times and one plan where the dwell times diﬀer
considerably for one patient is shown in ﬁgure 32.
(a) Equal dwell times (b) Dwell times diﬀer condiserably
Figure 32: An illustration of how the shape of the 400% isodose line diﬀers for
equal dwell times and inhomogeneous distribution of the dwell time values. The
yellow line is the isodose line for 400% of the prescribed dose, the red is 100% and
the blue is 75% of the prescribed dose. The pink dotted line is the ctv.
According to ctv V400, there are more inhomogeneities of dwell time values
in ipsa1 and ipsa2. As expected, the volume is smaller for edt, since for this plan
the dwell time distribution is homogeneous. ipsa3 is a plan suggested to decrease
the inhomogeneity in dwell time values. ext V400 for ipsa3 is only slightly
greater than ext V400 for edt, indicating that the maximum dose constraint
had an eﬀect.
Diﬀerent suggestions have been proposed in order to obtain homogeneous dis-
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tribution of dwell time values, but some of them are time consuming, which then
removes some of the advantage of using ipsa. In this study, setting a maximum
dose within the target volume was tested, and it seems like this lead to less inho-
mogeneity in dwell time values. This constraint does not lead to a homogeneous
distribution, but from ﬁgure 29 and 30 it is evident that the possibility for shap-
ing the dose distribution should be available. Inhomogeneous distribution in dwell
time values is then inevitable.
A dwell time gradient restriction ﬁlter is available for a treatment planning
system that is expected to produce solutions with smooth changes of dwell times
along the catheter, preventing dominating source dwell positions. This should
enable the creation of better security in the delivery dose distribution, without
having to compromise to the optimization performance [33].
2D plots The four treatment plans have diﬀerent advantages and disadvantages.
One has better target coverage, another spares the oars more. To be able to
determine which treatment plan will give the best starting point for most patients,
factors previously discussed should be considered in relation to one another. One
plan might have poor target coverage due to nearby positioning of one of the
oars. Dose to oars, target coverage and irradiated normal tissue all contribute
in determining the quality of the treatment plan.
2D plots are suggested when assessing plan quality to obtain more information
than using one index alone. A plot makes it possible to consider more factors,
while still being able to separate them. coin(weight) includes target coverage and
irradiated normal tissue in a suitable way. This index is plotted versus oarD2 cm3 ,
and this plot will provide much information on the treatment plan (chapter 4.3.2
and appendix E).
In the plots a vertical line is drawn, indicating tolerance limit for oarD2 cm3 in
the given oar. The horizontal line in the plots is the total mean for coin(weight)
for all four treatment plans (0.69). Points in the upper left square thus represent
treatment plans that fulﬁll the dose constraints for the oar and have a better
coin(weight) than the average.
More points in the upper left square will signify a generally better treatment
plan, and in table 6 points in the upper left square have been summed up. When
evaluating the information with respect to each other, it is evident that ipsa1
and ipsa3 will give better starting points for treatment planning. It is diﬃcult to
distinguish between ipsa1 and ipsa3 from these plots. The plots show that edt
is not a good choice due to low target coverage, and ipsa2 is not a good choice
due to too high doses to oars.
Summary Since tolerance limit to one or more oars has been exceeded for 82%
of the treatment plans for ipsa2, this procedure should be rejeceted. The target
coverage is better, but reduction of dose is necessary due to the oars, which then
will result in loss of target coverage.
The results for ipsa3 was as expected. Inhomogeneity in dwell times were
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reduced using this plan, but loss of target coverage then occurred. It is diﬃcult
to distinguish between ipsa1 and ipsa3, one having the better target coverage,
the other sparing surrounding tissue more. Due to the reduction in high dose
areas, ipsa3 will be preferable.
edt is not a good suggestion. Little normal tissue is irradiated and the distri-
bution of dwell times is homogeneous, but target coverage is poor. ipsa3 is better
regarding the oar, indicating that adapting the dose distribution to the patient's
individual anatomy is useful. Manual alteration will be necessary for many edt
treatment plans. Still, edt is an option available in Masterplan. An extra licence
needs to be purchased to be able to use ipsa.
5.4 Exclusion of non-tissue material
Non-tissue material (applicator and vaginal packing) constitute a considerable
part of the volume irradiated in brachytherapy of cervical cancer. When for
instance evaluating volume receiving the prescribed dose, it is important to know
if this volume includes or excludes the non-tissue material. In table 8 values have
been calculated, when including and excluding the non-tissue material.
The treatment plans would be rated the same way, since ipsa2 ≥ ipsa1 ≥
ipsa3 ≥ edt for both values that includes or excludes non-tissue material.
As expected, all dose and volume values where the non-tissue material is
included is greater than the values where non-tissue material has been excluded,
ctv V100 and ctv V400 having the largest diﬀerences. If these values were to
be compared with other studies, data including this material would give false
positives. For example, tc is higher when including the non-tissue material, since
non-tissue material within ctv will most likely be fully covered, resulting in a
false better target coverage. It is evident that full coverage of the applicator is
irrelevant when it comes to the quality of the treatment.
High dose areas, even if situated within ctv, is unwanted since the clinical
consequence is unknown. From the table, a substantial amount(approximately one
half) of the regions receiving 400% of the prescribed dose is within the applicator,
and from this it is evident that not excluding the non-tissue material will give
misleading results, and the non-tissue volume should be excluded to get more
correct results. Non-tissue material was manually delineated and subtracted from
the parameters in this study. There exist a modality with predeﬁned applicators
with information on applicator volume, such that exclutions of applicator material
can be done automatically.
As previously stated, when comparing treatment plans with each other irradi-
ated non-tissue material will not alter the conclusions, but if the actual measure
of the values were to be considered, non-tissue material should be excluded in
order to get more reliable numbers.
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5.5 Further study
Diﬀerences in mean values of dose and volume parameters between the diﬀer-
ent treatment plans are not statistically signiﬁcant for all values evaluated here.
However, using these numbers together with the plots and dose to the oar, a
tendency is found. Gathering more information would have been informative.
Target optimization will be avaible in Masterplan for the customers in June
2009. This may be a better alternative than edt, but does not take oars into
consideration. It would have been interesting to assess this algorithm and compare
it to ipsa1 and ipsa3. It is assumed that ipsa will give a better treatment plan,
but the eﬀect of this is not known.
Instead of searching for one set of dose constraints adequate for all cervical
cancer patients, it might be possible to obtain several sets of diﬀerent dose con-
straints. Which set to use could result from a parameter, e.g. there could be
diﬀerent sets of dose constraints for diﬀerent width of target volumes. The plan
created by ipsa might then be more adequate for the patient.
58
6 Conclusion
By comparing the dose distributions calculated by Masterplan and Plato, devi-
ations was found in certain regions. When these regions were examined more
carefully, they were found to be of no clinical relevance for brachytherapy for
cervical cancer and these deviations are therefore not important. In clinically rel-
evant areas, dose distributions calculated by Masterplan and Plato were similar.
The two computer programs simulates the dose distribution for the two diﬀerent
sources that were to be compared, and therefore the dose distribution for the
source types themself should be similar in clinical relevant areas. Simulating the
GammaMed source used for treatment at St. Olavs Hospital by the Nucletron
source available in Masterplan should be feasible. Dose measurements support
this statement.
Treatment plans with diﬀerent dose constraints created by the ipsa algorithm
have been evaluated in this study. In addition to target coverage, sparing oars
and high dose areas have been of particular interest. One ipsa optimized treat-
ment plan was found to give adequate dose distribution on average and is consid-
ered to be a better starting point for at treatment plan than the other suggestions.
This plan included a constraint diminishing high dose areas and conservative con-
straints to oars in addition to dose constraints for target coverage.
The ipsa plans were compared to a conservative treatment plan with equal
dwell times where the dose was prescribed to the target surface. This plan will
result in a poor starting point when creating a treatment plan in contrast with
the ipsa optimized treatment plans.
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A A calculation example of accumulated charge to dose
rate in water
Parameters:
Calibration date for the source 15.12.2008
Date of measurements 19.03.2009
Days since calibration 94.5 d
Half life of 192Ir 73.831 d
Decay factor from table 2.43
Pressure, P 103.58 kPa
Temperature, T 21.3 ◦C
Accumulation time, t 60 s
Calibration factor for air-kerma rate, Nk 43.8 · 106 Gy/C
Average of accumulated charge 1.159 nC
Noise 5.3 pC
Average of accumulated charge, corrected 1.154 nC
By using equation (3) in section 2.2.4, the correction factor for pressure and
temperature is
kTP =
(273.2 + 21.3)
(273.2 + 20)
· 101.3
103.58
= 0.982
The decay factor can be calculated from equation (5).
1
Fdecay
=
1
e−ln2 · 94.5/73.83 = 2.43
This is the same as the decay factor from the table. Thus, from equation (4)
and (5) the dose rate is found.
D˙W,Q =
1.1537 · 10−9
60/3600
· 43.8 · 106 · 1.11 · 1 · 0.982 · 1 · 1 · 2.43 = 8.03Gy/h.
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B Calculation of tolerance limit per fraction for oars
To calculate the total biological weighted dose from both external and internal
radiation therapy, each fraction of external and internal radiotherapy has to be
evaluated, and a biologically weighted dose (doses relative to 2 Gy fractions, with
the same α/β-value) has to be calculated. These calculated values from each
fraction can be added, arriving at the total biologically dose that was given to the
volume of interest.
The maximum dose, d, an oar can receive in each of the four fractions of
brachytherapy can be found as shown in the following.
Parameters:
Number of brachytherapy fractions 4
Dose to ctv per brachytherapy fraction 5 Gy
α/β-value for normal tissue 3
α/β-value for tumor tissue 10
Tolerance limit for bladder 90 Gy
Tolerance limit for rectum and sigmoid 75 Gy
Total dose from external treatment (25 fractions) 50 Gy
The tolerance limit per fraction for the bladder can then be calculated from
equation (1) :
EQD2(internal) = 90 Gy − 50 Gy = 40 Gy
EQD2 = 4d · d+ 32 + 3 = 40 Gy
d2 + 3d = 50
d = 5.7
The minimum dose in the 2 cm2 volume that receives the highest dose should
therefore not be greater than 5.7 Gy per fraction for the bladder. To be conser-
vative, a worst case scenario is considered, i.e. it is assumed that the highest dose
will occur in the same part of the organ for every fraction.
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C Data ﬁle from comparison of dose calculated by Mas-
terplan and Plato
The data ﬁle for the plots in ﬁgure 22 and 23 in chapter 4.1 are given in table 9.
Absolute values of the diﬀerence between point doses calculated by Masterplan
and Plato are given in percentages of the point dose calculated by Plato.
Table 9: Deviations for given points in calculated dose by Masterplan and Plato
Point source Catheter
x z Deviation (%) x z Deviation (%)
5 25 0.77 1 1.7 2.5
10 25 0.34 2 3.5 2.7
15 25 0.2 4 6.9 0.5
20 25 0.31 8 13.8 0.2
25 25 0.53 16 27.6 0.2
30 25 0 0.5 1.9 15.8
5 0 0.55 1 3.9 6.6
10 0 0.22 2 7.7 1.7
15 0 0.16 4 15.4 0.3
20 0 0.17 8 30.8 0
25 0 0.32 16 61.6 0.2
30 0 0.3 0.5 3 11.1
0 2 126.3 1 6 0.2
0 4 19.5 1.3 7.8 3
0 6 7.8 2 12 0.2
0 7 5.1 4 24 0.6
0 8 3.4 0.3 3.3 24.2
0 10 3.2 0.5 5.5 11.9
0 12 3.1 0.7 8 8.7
0 14 3 1 11 0.1
0 16 2.9 5 55 1.9
0 18 2.7 1 -1.7 10.8
0 20 2.6 1.5 -2.6 8
0 22 2.2 2 -3.5 5.7
0 24 1.8 3 -5.2 3.7
0 26 2 4 -6.9 2.9
0 28 2.7 8 -13.8 1.9
0 30 3.6 16 -27.6 2.2
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Point source Catheter
x y Deviation (%) x y Deviation (%)
0 35 0 0.5 -1.9 18.7
0 40 1.1 0.7 -2.9 9.1
0 60 2.1 1 -3.9 5.5
2 20 1.8 0.7 -4.5 4.8
4 2 1.6 1 -6 3
4 4 2.5 1.3 -7.8 1.7
4 6 1.8 2 -12 0.6
4 8 1.5 0.3 -3.3 1.8
4 10 1.8 0.5 -5.5 0.8
4 20 1.4 0.7 -8 3.2
0 -2 16.1 1 -11 6.7
0 -4 9.4 2 -22 5.9
0 -6 8 1 51.7 6.1
0 -8 6.9 2 53.5 4.3
0 -10 7.3 4 56.9 1.7
0 -12 12.4 8 63.8 0.7
0 -14 19.4 16 77.6 1.3
0 -16 27.4 0.5 51.9 21.5
0 -18 36.3 1 53.9 6.7
0 -20 45.9 1.5 55.8 3.1
0 -22 41.7 2 57.7 2
0 -24 37.3 4 65.4 1.1
0 -26 34.6 8 80.8 1.7
0 -28 33.5 0.5 53 13.5
0 -30 32.2 0.7 54.4 5.8
0 -35 28.2 1 56 3
0 -40 27.2 1.3 57.8 2
0 -60 13.8 2 62 2
0 -80 13.1 0.3 53.3 14.9
2 -2 7 0.4 54.4 7.3
2 -4 7.5 0.5 55.5 3.5
2 -8 5.4 0.7 58 1.6
2 -12 3.8 1 61 2.3
2 -16 2 1 48.3 6.2
2 -20 0.5 2 46.5 0.7
2 -24 2.7 4 43.1 0.1
2 -28 6 8 36.2 0.1
2 -32 7.4 16 22.4 0.1
2 -36 8 0.5 48.1 12.4
2 -40 9.5 1 46.1 0.8
2 -44 13.2 2 42.3 0.5
2 -48 15.7 4 34.6 0.3
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Point source Catheter
x y Deviation (%) x y Deviation (%)
2 -52 14.8 8 19.2 0.1
2 -56 10.8 0.5 47 16.6
2 -60 6.1 1 44 5.4
2 -64 3.9 1.3 42.2 0.3
2 -68 3.3 2 38 1.9
4 -2 2.6 0.3 46.7 21
4 -4 3.3 0.5 44.5 21.2
4 -8 4.1 0.7 42 6.8
4 -12 2.5 1 39 5.5
4 -16 2.3 0 -2 14.8
4 -20 2.6 0 -4 11.7
4 -24 2.7 0 -6 13.5
4 -28 1.4 0 -8 16.3
4 -32 0.7 0 -10 19.9
4 -36 0.5 0 -12 24.5
4 -40 0.2 0 -14 28.9
4 -44 0.6 0 -16 31.6
4 -48 1.8 0 -18 33
4 -52 2.4 0 -20 34
4 -56 1.7 0 -22 31.9
4 -60 0.1 0 -24 29.9
4 -64 0.9 0 -26 28.5
4 -68 1.6 0 -28 27.4
1 1.7 5.07 0 -30 26.5
2 3.5 4.46 0 -60 8.6
4 6.9 0.75 0 -90 3
8 13.8 1.13 2 -2 6.1
16 27.6 0.08 2 -4 5.8
0.5 1.9 20.52 2 -8 2.2
1 3.9 7.79 2 -12 0.6
2 7.7 1.64 2 -16 3.2
4 15.4 2.2 2 -20 5.4
8 30.8 0.12 2 -24 7.3
0.5 3 15.28 2 -28 8.6
1 6 3.16 2 -32 9.1
1.3 7.8 1.42 2 -36 9.3
2 12 2.67 2 -40 9.5
3 18 0.21 2 -44 8.8
4 24 0.9 2 -48 7.6
0.3 3.3 17.61 2 -52 5.9
0.5 5.5 4.29 2 -56 4.3
0.7 8 1.03 2 -60 2.6
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Point source Catheter
x y Deviation (%) x y Deviation (%)
1 11 2.95 2 -64 1.6
1.5 16.5 0.35 2 -68 0.4
2 22 1.46 4 -2 2.6
1 -1.7 11.63 4 -4 2.8
2 -3.5 7.09 4 -8 2.7
4 -6.9 4.25 4 -12 1.6
6 -10.4 2.58 4 -16 1.3
8 -13.8 1.77 4 -20 1
16 -27.6 2.04 4 -24 0.5
0.5 -1.9 19.83 4 -28 0
1 -3.9 7.86 4 -32 0.3
2 -7.7 5.54 4 -36 0.3
3 -11.6 3.4 4 -40 0.4
4 -15.4 2.41 4 -44 0
8 -30.8 2.36 4 -48 0.5
0.5 -3 10.82 4 -52 1.1
1 -6 8.32 4 -56 2.1
1.3 -7.8 7.64 4 -60 2.7
1.7 -10.2 4.8 4 -64 3.4
2 -12 3.8 4 -68 4.2
3 -18 0.27 0 52 123.7
4 -24 0.27 0 53 27.8
0.3 -3.3 4.39 0 54 15.7
0.5 -5.5 7.4 0 55 9
0.7 -8 5.67 0 56 6
0.8 -9 3.6 0 57 4.2
1 -11 1.5 0 58 3.1
1.5 -16.5 0.12 0 60 2.8
2 -22 1.11 0 62 2.6
0 64 2.3
0 66 2
0 68 1.7
0 70 1.4
0 72 1
0 74 0.7
0 76 0.4
0 78 0.1
0 80 0.2
0 90 2.5
2 52 3.9
2 54 4
2 56 2.7
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Point source Catheter
x y Deviation (%) x y Deviation (%)
2 58 2
2 60 2.1
4 52 2
4 54 2.5
4 56 1.9
4 58 1.6
4 60 1.6
5 25 0.1
10 25 0
15 25 0.2
20 25 0.1
25 25 0.1
30 25 0.2
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D P-values for the diﬀerence in means
The P-values (6 pairwise comparisons) calculated for the diﬀerence in mean values
for dose and volume parameters from the four treatment plans in table 5 in chap-
ter 4.3. The P-value is outlined for the values where the diﬀerence is signiﬁcant.
CTV D90 EDT IPSA1 IPSA2 IPSA3
IPSA1 0.0004 0.2 0.6
IPSA2 0 0.009
IPSA3 0.01
CTV V100 EDT IPSA1 IPSA2 IPSA3
IPSA1 0.5 0.9 1.0
IPSA2 0.2 0.8
IPSA3 0.7
CTV V400 EDT IPSA1 IPSA2 IPSA3
IPSA1 0.8 0.9 0.8
IPSA2 0.4 0.4
IPSA3 1
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EXT V100 EDT IPSA1 IPSA2 IPSA3
IPSA1 0.002 0.2 0.6
IPSA2 0 0.01
IPSA3 0.054
Bladder EDT IPSA1 IPSA2 IPSA3
IPSA1 0.9 0.4 0.6
IPSA2 0.1 0.041
IPSA3 1.0
Rectum EDT IPSA1 IPSA2 IPSA3
IPSA1 0.058 0.7 0.9
IPSA2 0.003 0.3
IPSA3 0.2
Sigmoid EDT IPSA1 IPSA2 IPSA3
IPSA1 0.08 0.4 1.0
IPSA2 0.001 0.2
IPSA3 0.2
TC EDT IPSA1 IPSA2 IPSA3
IPSA1 0 0.1 0.9
IPSA2 0 0.02
IPSA3 0.0004
COIN EDT IPSA1 IPSA2 IPSA3
IPSA1 0.3 1.0 0.9
IPSA2 0.2 0.9
IPSA3 0.08
COIN weight EDT IPSA1 IPSA2 IPSA3
IPSA1 0.001 0.5 1.0
IPSA2 0 0.4
IPSA3 0.002
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E Plots of coin(weight) vs. oar
The plots for coin(weight) versus rectum and sigmoid used to count the total
number of plans positioned in upper left square in table 6 are shown in ﬁgure 33
and ﬁgure 34.
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(a) IPSA1 (b) IPSA2
(c) IPSA3 (d) EDT
Figure 33: COIN(weight) vs. minimum dose in the volume (2 cm3) receiving the
highest dose for the rectum. Points in the upper left square fulﬁll the constraints
with respect to the oar and coin(weight) is better than average.
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(a) IPSA1 (b) IPSA2
(c) IPSA3 (d) EDT
Figure 34: COIN(weight) vs. minimum dose in the volume (2 cm3) receiving the
highest dose for the sigmoid. Points in the upper left square fulﬁll the constraints
with respect to the oar and coin(weight) is better than average.
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